



**Vaccines and Global Health: The Week in Review**  
**26 July 2025 :: Issue 809**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

## *Milestones, Perspectives*

.....  
.....

### Gavi Board focuses on priority health impact as guiding principle in a resource constrained world

- **Gavi's Board today agreed to a series of adjustments to its objectives for its next five-year period (2026–2030)**
- In addition to programming adjustments, **the Board approved a new strategy for supporting fragile & humanitarian contexts, confirmed the introduction of RSV vaccines and gave a green light to the establishment of an Mpox vaccine stockpile**
- Gavi Board Chair Professor José Manuel Barroso: "I want to thank our donors for the significant amount of support already pledged and I am hopeful that with the support of other donors that have not yet been able to pledge, Gavi can look forward to its most ambitious strategic period yet."

Geneva, 25 July 2025 – The Board of Gavi, the Vaccine Alliance this week endorsed a series of **adjustments to bring Gavi's strategy for its next five-year period (2026-2030) in line with available resources while it continues to engage with donors that have not yet been able to pledge support.** The Board also passed a range of measures including a new strategic approach to protecting children in fragile and humanitarian settings, introducing RSV vaccines and establishing a stockpile for Mpox vaccines.

Commenting on the two-day Board Meeting, Professor José Manuel Barroso said: "I am confident the decisions taken by Gavi's Board represent the **best way of sustaining Gavi's mission to save lives and protect health through immunisation in a time of constrained resources.** I want to thank our donors for the significant amount of support already pledged and I am hopeful that with the support of other donors that have not yet been able to pledge, Gavi can look forward to its most ambitious strategic period yet."...

### *Adjusting for a resource-constrained world*

Gavi's donors have committed significant volumes of 5-year funding, **however in response to an estimated shortfall of US\$ 3 billion for the coming five-year strategy period, Gavi's Board held a special meeting to evaluate a range of options for bringing strategic objectives into line with committed resources.**

With health impact as a guiding principle and the importance of the Gavi 6.0 strategy reaffirmed by the Board, **the pathway selected by the Board will see a slowdown in some Gavi-supported immunisation programmes.** In order to minimise this impact, Gavi will continue to engage with donors that have not yet been able to pledge support due to their domestic budgetary cycles, with the aim of fully meeting its US\$11.9 billion fundraising target.

### *Fragile and Humanitarian approach: shifting gears*

In 2024, Gavi implementing countries achieved historic progress: more people were protected against more diseases than ever before, and immunisation coverage is steadily recovering from pandemic-era setbacks. However, fragility, conflict, and demographic pressures continue to limit access for millions.

**Building on lessons learned, Gavi's Board agreed to sharpen its focus on children living in fragile and humanitarian settings.** The new strategic approach will deepen engagement to immunise children in crisis-affected settings, expand outreach to children up to age five, increase support to underserved subnational regions, and strengthen collaboration with humanitarian actors. **It will also introduce a new agile funding tool – the Gavi Resilience Mechanism - to respond**

**rapidly to unforeseen country needs** such as outbreaks and emergencies that are not covered through existing support mechanisms. This includes middle-income countries facing acute shocks. **These shifts aim to embed immunisation as a core component of humanitarian health response and enhance the Alliance's capacity to operate in complex and volatile environments.**

### ***Introduction of RSV on the horizon***

In a step to protect newborns and infants against one of the leading causes of pneumonia, the Board approved the **opening of a funding window for the establishment of a Respiratory Syncytial Virus (RSV) maternal vaccine programme.** The decision follows the prequalification of the first RSV maternal vaccine in March 2025 and paves the way for country introductions to begin in the near future.

### ***Moving forward with an mpox stockpile***

To further support global health security, the Gavi Board approved the **opening of a funding window for the establishment of an mpox emergency vaccine stockpile.** Proposed to be managed by the International Coordinating Group (ICG), the stockpile will enable the rapid deployment of vaccines at the outset of an outbreak. The stockpile complements ongoing efforts by Gavi and global and regional partners to tackle the on-going mpox emergency in Africa and through response to future outbreaks, has the potential to prevent thousands of severe cases and significantly reduce transmission in high-risk settings.

### ***A New Health System Strategy***

The Board also approved **Gavi's first ever health systems strategy to help countries reach children with lifesaving vaccines,** regardless of where they live and to sustain high and equitable vaccination coverage. The strategy identifies key priorities for Gavi support and includes important shifts to support countries, including more differentiated and tailored programming, a simplified funding model, a deliberate approach to primary healthcare, alignment with other funding partners, a focus on innovation and strengthened measurement and learning.

### ***New funding policies and evolving the way Gavi works with its partners***

In light of ongoing economic pressures, revisions to Gavi's eligibility, transition, and co-financing policies were additionally approved, **requiring countries to take on greater financial responsibility for their vaccination programmes.** To help countries plan more effectively for these programmes, a revised Health Systems and Immunization Strengthening (HSIS) policy with consolidated funding levers and simplified processes, received final board approval, paving the way for official implementation in 2026. **The board also approved a new partnership and accountability framework to bolster transparency and drive measurable impact across global, regional, and country-level partnerships.**

### ***Appointments and process updates***

Yibing Wu was reappointed as Chair of the Investment Committee and as an Unaffiliated Board Member Omar Abdi was reappointed as Vice Chair of the Board and as Chair of the Governance Committee

.....  
.....

### **Nature**

Volume 643 Issue 8073, 24 July 2025

<https://www.nature.com/nature/volumes/641/issues/8073>

Editorial 22 Jul 2025

## **Help save 2 million lives: close the vaccine funding gap**

*Gavi, the vaccine provider for the world's poorest people, needs an extra US\$3 billion to protect infants and other vulnerable groups. More donors must step up.*

This year was never going to be easy for Gavi, the Vaccine Alliance, the global-health organization that has vaccinated more than one billion children against diseases such as polio, diphtheria, measles and Ebola. As the organization, based in Geneva, Switzerland, celebrates its 25th birthday — and the nearly 19 million lives that its inoculations have saved during its time — it finds itself US\$3 billion short of its \$12-billion target budget for 2026–30.

If the shortfall cannot be filled, Gavi will need to cut lifesaving programmes, and the world will probably see a resurgence of disease, illness and avoidable deaths. “For every \$1.5 billion less, your ability to save 1.1 million lives is compromised,” Gavi chief executive Sania Nishtar told *Nature*. “That’s a lot of children put in harm’s way.”

At the start of the year, Gavi’s public and private donors were already stretched by competing needs, owing to factors from economic instability to armed conflict and climate change. But fears mounted in March, when news broke that the United States, one of its biggest donors, would abandon a previous pledge of at least \$1.58 billion. This was confirmed at a 25 June summit of donors in Brussels, where US health secretary Robert F. Kennedy Jr, who has long campaigned against some vaccines, criticized the organization for not taking vaccine safety seriously.

Gavi’s leadership quickly issued a statement identifying misrepresentations in Kennedy’s words and clarifying that it does not distribute vaccines unless they have been recommended by the independent vaccine advisory panel of the World Health Organization (WHO), which evaluates safety and efficacy “through a rigorous, transparent and independent process”.

Even without the US withdrawal, Gavi was \$1.5 billion off target. Now, it must find around twice that. Gavi’s board is meeting this week to sift through its options. There is some good news: Gavi has more donors now than in past years, and some have said that they can contribute at a later time. Moreover, some manufacturers have agreed to lower the cost of their vaccines for Gavi.

However, in the short term, global-health advocates will now need to find creative ways to pool their resources, coordinate efforts and continue to invest in innovation to squeeze the most they can from limited funds. Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and their many global-health partners will have to coordinate carefully to ensure low- and middle-income countries receive the vaccines they need. “Organizations like mine are going to be put through our paces and tested in a way that we haven’t been tested before,” says Aurélia Nguyen, deputy chief executive of CEPI, based in Oslo, which works to accelerate the development of vaccines against emerging infectious diseases.

In the chaos left behind by the US plan to withdraw from the WHO and other global-health programmes, it could be tempting to focus on existing funding priorities. But there is also a pipeline of new and upcoming vaccines that could save yet more lives. In 2021, the WHO recommended the first vaccine against malaria, which is now being rolled out to millions of young children in 20 African countries. Governments are clamouring for doses — malaria kills roughly 600,000 people every year. Hopes are also high that an experimental tuberculosis vaccine, now in late-stage clinical trials, could help to combat one of the world’s most deadly diseases. Tuberculosis kills more than one million people a year globally.

Now is not the time to take the foot off the accelerator on such innovations — which is another reason more coordination and cooperation is needed. Declining vaccination rates in poor countries not only put the lives of vulnerable people — especially children — at risk from infectious disease, but can also raise the danger of disease outbreaks around the world.

The rapid response to a 2024 Marburg virus outbreak in Rwanda, with only ten days between the declaration of an outbreak and the first vaccination (*C. T. Nutt N. Engl. J. Med.* **392**, 625–627; 2025), stands as a positive example of what can be achieved when countries have the resources and preparation to coordinate and therefore respond aggressively. That outbreak — one of the largest ever of Marburg virus — was quenched by the Rwandan health authorities in less than three months. If the response had not been so swift, the outbreak could have spread farther, taken more lives and drained more resources.

Gavi will continue to search for places to cut costs. At the same time, some African countries, which themselves have contributed more than \$1 billion to Gavi since 2008, are exploring how their health-care systems will need to adapt to this financial climate, according to Jean Kaseya, director-general of the Africa Centres for Disease Control and Prevention, based in Addis Ababa.

But because only 3% of Gavi's budget goes to administrative costs, a relatively low figure compared with other charities, that leaves little to cut before important programmes are under threat. More funds will be needed, so there is an opportunity for donors to step forward to fill the gap, Nishtar says. "We're preparing for all scenarios, because that's the responsible thing to do," she says. "But we have every reason to hope for a very positive future."

If donors care about the health and well-being of present and future generations, the responsible thing will be not to settle for a worst-case scenario, but to provide Gavi with what it needs. "For us, Gavi is a game changer," Kaseya says.

.....  
.....

## Cholera

### [Multi-country outbreak of cholera, external situation report #28 -24 July 2025](#)

# Multi-country outbreak of cholera



External Situation Report n. 28, published 24 July 2025

Cases – 305 903  
Since Jan. 2025

Deaths – 3522  
Since Jan. 2025

Countries affected – 28  
Since Jan. 2025

Population at risk  
1 billion

Global risk –  
Very high

## Overview

Data as of 29 June 2025

- **In June 2025 (epidemiological weeks 23 to 26), a total of 62330 new cholera and/or acute watery diarrhoea (AWD) cases were reported from 20 countries**, territories, areas (hereafter countries) across three WHO regions, showing an 8% decrease from May. The Eastern Mediterranean Region registered the highest number of cases, followed by the African Region and the South-East Asia Region. The period also saw 527 cholera-related deaths globally, an 8% decrease from the previous month.
- In June 2025, the number of cholera cases was 21% lower, while the number of deaths was 38% higher compared to June 2024, when 78 403 cases and 381 cholera-related deaths were reported across 21 countries.
- From 1 January to 29 June 2025, a cumulative total of 305 903 cholera cases and 3522 deaths were reported from 28 countries across three WHO regions, with the Eastern Mediterranean Region

recording the highest numbers, followed by the African Region and the South-East Asia Region. No cases were reported in other WHO regions.

- The overall cholera data remain incomplete due to underreporting and reporting delays. Additionally, extreme weather events and conflict, as experienced in several cholera affected countries, have resulted in low or no reporting from some areas. **Given these complexities, the data presented here likely underestimates the true burden of cholera and should be interpreted with caution.**
- **In June 2025, the average stockpile of Oral Cholera Vaccine (OCV) was 2.9 million doses, below the emergency stockpile level of five million for the first time in 6 months.**

### ***Operational updates***

#### ***... Vaccination***

- The global OCV stockpile averaged 2.9 million doses in June 2025, with the five weeks below the target of five million doses that should be available at all times for outbreak response. After six consecutive months above, this is the first month with an average stock level below the emergency stock level.
- **Between January and June 2025, 29 new emergency requests were submitted – compared to nine in 2024** – by 9 countries: Angola (3), DR Congo (3), Ethiopia, Ghana (4), Mozambique, Myanmar, Nigeria, South Sudan (10), Sudan (5) collectively seeking 36 million doses for single round campaigns (compared to 22 million in 2024). Twenty-eight requests were approved, while one was not approved by the International Coordinating Group (ICG) on Vaccine Provision.
- **Since the start of 2025, fifteen countries (Angola, Bangladesh, DR Congo, Ethiopia, Ghana, Haiti, Kenya, Malawi, Mozambique, Myanmar, Niger, Nigeria, South Sudan, Sudan and Zambia) have conducted 37 reactive vaccination campaigns, targeting a total of 28 million people.** Due to limited vaccine availability, only single-dose vaccination campaigns have been approved by ICG.
- Despite these efforts, **the growing demand for OCV continues to exceed supply, severely constraining preventive vaccination campaigns. Urgent expansion of vaccine production remains critical.**

.....  
.....  
.....

### **U.S. Immunization and Public Health Governance/Policy/Funding**

*Given the continuing extraordinary situation in the U.S., we are establishing a separate section of the digest to capture and organize key content.*

.....

### **White House, HHS, FDA, CDC+**

#### **White House**

*Presidential Actions – Executive Orders; Memoranda; Proclamations*  
*No new digest content identified.*

#### **HHS**

##### *News*

**[HHS Adopts ACIP Recommendation to Remove Thimerosal from All U.S. Influenza Vaccines](#)**

July 23, 2025 Press Release

WASHINGTON, DC—JULY 23, 2025—U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. took action Tuesday signing the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) recommendations to remove the mercury-based preservative thimerosal from all influenza vaccines distributed in the United States.

This move follows a 5-1-1 vote at the ACIP's June 25-26 meeting at CDC headquarters in Atlanta, where committee members voted that all children 18 years and younger, pregnant women, and adults receive only single-dose influenza vaccines free of mercury. Secretary Kennedy's signature formally adopts the recommendation into federal health policy, fulfilling a commitment to restore trust with Americans by removing risk while sustaining access to vaccines.

"After more than two decades of delay, this action fulfills a long-overdue promise to protect our most vulnerable populations from unnecessary mercury exposure," Secretary Kennedy said. "Injecting any amount of mercury into children when safe, mercury-free alternatives exist defies common sense and public health responsibility. Today, we put safety first."

The effort to remove mercury from childhood vaccines began in 1999 when the U.S. Public Health Service, the American Academy of Pediatrics (AAP), and vaccine manufacturers jointly agreed that any potential risk from mercury warranted its removal as soon as possible. This marks the final step to remove mercury from all vaccines given to Americans.

Secretary Kennedy's newly appointed ACIP members broke with long-standing inaction by voting to remove mercury entirely from all influenza vaccines, fulfilling the 1999 pledge and aligning U.S. policy with that of Europe, which phased out mercury additives years ago.

Vaccine manufacturers have confirmed they have the capacity to replace multi-dose vials containing mercury, ensuring the Vaccines for Children (VFC) program and adult vaccine supplies will remain uninterrupted.

The ACIP, composed of leading medical and public health experts, advises the CDC on vaccine safety, efficacy, and clinical necessity. This historic decision marks a critical step toward enhancing public confidence in vaccines and advancing the nation's commitment to safer immunization practices.

"With the U.S. now removing mercury from all vaccines, we urge global health authorities to follow this prudent example for the protection of children worldwide," Secretary Kennedy added.

Secretary Kennedy has approved all recommendations issued from the April ACIP meeting. Other recommendations from the committee's June meeting are currently under review.

**NIH** [to 26 July 2025]

<http://www.nih.gov/>

*News Releases*

*No new digest content identified*

**FDA**

[\*Press Announcements\*](#)

July 21, 2025 –

[\*\*Stanford faculty member George Tidmarsh, M.D., Ph.D. named Director of Center for Drug Evaluation and Research\*\*](#)

**CDC/ACIP** [to 26 July 2025]

<http://www.cdc.gov/media/index.html>

*Latest News*

*No new digest content identified.*

**ACIP Meetings** [to 26 July 2025]

*Next ACIP Meetings*

:: August/September (dates TBD)

:: October 22-23

## FDA VRBPAC

*Advisory Committee Calendar*

***Advisory Committee Calendar has no meetings posted for this Advisory Committee***

## FDA Pediatric Advisory Committee Meeting

***Advisory Committee Calendar has no meetings posted for this Advisory Committee***

## National Vaccine Program Committee (NVAC)

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

***No 2025 meeting dates posted.***

## Advisory Commission on Childhood Vaccines (ACCV)

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

***Next ACCV Meeting - TBD***

## MMWR Weekly

<https://www.cdc.gov/mmwr/index2025.html>

***July 24, 2025 / No. 27***

*No new digest content identified.*

.....  
.....

## U.S. Congress

### House of Representatives

***mPox Vaccine Commitment – Letter from 47 Members of Congress*** [Editor's text bolding]

*July 23, 2025*

The Honorable Marco Rubio

Secretary of State

U.S. Department of State

2201 C Street NW, Washington, D.C. 20520

Dear Secretary Rubio:

**We write to urge immediate action to distribute all remaining viable mpox vaccines from the United States that were promised to African countries that are currently experiencing outbreaks.**

According to a July 17, 2025 *Politico* article, nearly 800,000 doses of the mpox vaccine that were originally pledged by the United States to African nations may go to waste.<sup>1</sup> **Critically, an estimated 220,000 of these vaccines could still be viable if the State Department acts without delay to ship these vaccines immediately.**

As you are aware, the current mpox outbreak in Africa has resulted in over 47,000 confirmed cases and nearly 1,900 suspected deaths, many among them children who are disproportionately impacted.<sup>2,3</sup> While the United States has largely contained its mpox outbreak, the unchecked spread in African communities poses a serious and growing global health threat – including to our own nation.

**This is a moral, strategic, and public health failure in the making.** Your agency has an ever shortening window of opportunity to act decisively and deliver lifesaving vaccines to people who need them. **Letting these vaccines expire while sitting on shelves is indefensible,** wasting taxpayer-

funded doses, undermining the United States' credibility abroad, and contradicting the entirety of your work while in the Senate.

**We urge you to act now and immediately ship viable mpox vaccines** to save lives and prevent needless suffering and death. Lives hang in the balance.

1 <https://www.politico.com/news/2025/07/17/us-has-wasted-hundreds-of-thousands-of-vaccines-meant-for-africahealth-officials-there-say-00460290>

2 *Id.*

3 [https://worldhealthorg.shinyapps.io/mpx\\_global/#sec-afr](https://worldhealthorg.shinyapps.io/mpx_global/#sec-afr)

.....

## U.S. Senate

*No new digest content identified.*

.....

.....

## U.S. Health Policy/Funding: Analysis & Tracking – KFF [Kaiser Family Foundation]

### ***Editor's Note:***

KFF released a number of analyses below following the milestone represented by the recently concluded legislative action considering rescission of previously approved, and in some cases already committed, funding for a range of U.S.-led global health programs and global health international organizations, including WHO, UNICEF, CEPI, Global Fund, etc.

One significant milestone ahead applies to most of the reports below: the results of the USG 90-day foreign aid review which will include recommendations concerning membership and financial support for a range of UN system and multilateral organizations. The report is targeted for August 3, 2025 but an earlier deadline was extended by 30 days. As KFF notes, it is unclear how or if Congress will respond to these recommendations when issued.

In parallel, KFF notes that "the proposed permanent dissolution of USAID and integration of any remaining USAID global health activities, including for MCH, into GHSD, raises several questions, including whether additional capacities will be provided to allow for the management and implementation of MCH and these other health programs at the State Department."

## **The Trump Administration's Foreign Aid Review: Proposed Reorganization of U.S. Global Health Programs**

July 23, 2025

...*What to Watch*

- **...Funding/President's budget request:** The administration's FY 2026 budget request includes a \$6.2 billion reduction in funding for global health and proposes to eliminate several funding lines. Final appropriation amounts for FY 2026 will be determined by Congress. **The administration also submitted its first rescission package to Congress, including proposed rescissions of \$400 million in FY 2025 Funding for PEPFAR and \$500 million in FY 2025 funding for other global health programs. Congress voted to amend the package, exempting PEPFAR funding as well as funding for maternal and child health, TB, malaria, and nutrition from the rescission, although \$500 million in family planning and other programs will be rescinded.**

- *Congressional oversight:* As budget and reorganization proposals and requests continue to circulate, members of Congress could choose to exert their own authority, including seeking further clarification and information about the potential impacts of proposed changes.

### The Trump Administration's Foreign Aid Review: Status of U.S. Global Maternal and Child Health Efforts

July 23, 2025

...*What to Watch*

- **...*Funding/Budget Request:*** The administration's FY 2026 budget request includes significant reductions in funding for global health, and does not include funding for bilateral maternal and child health efforts. Final appropriation amounts for FY 2026 will be determined by Congress. **The administration also submitted its first rescission package to Congress, including proposed rescissions of more than \$1 billion in FY 2025 funding for global health. Congress voted to amend the package, reducing that amount to \$500 million and exempting some program areas, including maternal and child health, from the rescission.**

### The Trump Administration's Foreign Aid Review: Status of U.S. Support for CEPI

July 23, 2025

...*What to Watch:*

**... *Funding/Budget Request:*** The administration's FY 2026 budget request includes significant reductions in funding for global health, and does not include funding for CEPI. Final appropriation amounts for FY 2026 will be determined by Congress. **The administration also submitted its first rescission package to Congress, including proposed rescissions of more than \$1 billion in FY 2025 funding for global health. Congress voted to amend the package, reducing that amount to \$500 million and exempting some program areas from the rescission though it is not yet known if CEPI will be exempted.**

### The Trump Administration's Foreign Aid Review: Status of U.S. Support for Gavi, the Vaccine Alliance

July 23, 2025

...*What to Watch:*

**...*Funding/Budget Request:*** The administration's FY 2026 budget request includes significant reductions in funding for global health, and does not include funding for Gavi. Final appropriation amounts for FY 2026 will be determined by Congress. The administration also submitted its first rescission package to Congress, including proposed rescissions of more than \$1 billion in FY 2025 funding for global health. **Congress voted to amend the package, reducing that amount to \$500 million and exempting some program areas, including Gavi as part of maternal and child health funding, from the rescission.**

***Replenishment:*** Gavi's June 2025 pledging conference raised \$9 billion in funding towards its \$11.9 billion target. Last year, the Biden administration pledged at least \$1.58 billion over five years to Gavi's replenishment. However, Secretary Kennedy announced that the U.S. will not provide additional funding to Gavi unless it changes its evaluation of vaccine science and safety, among other issues. In response, Gavi has stated that it relies on WHO's independent, science-based, global vaccine evaluation and recommendation process. In addition, individual country requests for vaccine support from Gavi are made in line with their own national immunization policies. While final U.S. funding amounts are determined by Congress, it remains to be seen how this will unfold over the next year.

## [The Trump Administration's Foreign Aid Review: Status of U.S. Support for the Global Fund to Fight AIDS, Tuberculosis and Malaria](#)

July 23, 2025

...*What to Watch:*

... **PEPFAR reauthorization and lapsed legislative requirements:** It is unknown if Congress will seek to reauthorize PEPFAR, which could afford it an opportunity to extend the time-bound provisions that apply to the Global Fund. It could also use another legislative vehicle to do so. Even without these requirements in place, the administration could still choose to follow them.

**Funding/Budget Request:** The administration's FY 2026 budget request includes significant reductions in funding for global health. While the request does not specify a funding amount for the Global Fund, it states that "Should the Administration decide to provide contributions to the Global Fund in FY 2026, it would ensure the United States is only contributing its fair share by leveraging \$1 from the United States for every \$4 from other donors, instead of the current \$1:\$2 matching pledge, up to a total amount of \$2.4 billion over three years." Final appropriation amounts for FY 2026 will be determined by Congress.

*Replenishment.* The Global Fund's upcoming pledging conference later this year will be an important moment for the organization in determining its budget for the next five years.

## [The Trump Administration's Foreign Aid Review: Status of Global Health Security/Pandemic Preparedness](#)

July 23, 2025

...*What to Watch:*

... **Funding/Budget Request:** The administration's FY 2026 budget request includes significant reductions in funding for global health, including a \$500 million reduction for GHS. Final appropriation amounts for FY 2026 will be determined by Congress. The administration also submitted its first rescission package to Congress, including proposed rescissions of more than \$1 billion in FY 2025 funding for global health. **Congress voted to amend the package, reducing that amount to \$500 million and exempting some program areas from the rescission, although global health security was not listed among those program areas.**

## [The Trump Administration's Foreign Aid Review: Status of the President's Malaria Initiative \(PMI\)](#)

July 23, 2025

...*What to Watch*

...**Funding/Budget Request:** The administration's FY 2026 budget request includes significant reductions in funding for global health, including a \$381 million reduction for malaria. Final appropriation amounts for FY 2026 will be determined by Congress. The administration also submitted its first rescission package to Congress, including proposed rescissions of more than \$1 billion in FY 2025 funding for global health. **Congress voted to amend the package, reducing that amount to \$500 million and exempting some program areas, including malaria, from the rescission.**

## [The Trump Administration's Foreign Aid Review: Status of U.S. Global Tuberculosis Efforts](#)

July 23, 2025

...*What to Watch*

- **...Funding/Budget Request:** The administration's FY 2026 budget request includes significant reductions in funding for global health, including a \$228 million reduction for TB. Final appropriation amounts for FY 2026 will be determined by Congress. The administration also submitted its first rescission package to Congress, including proposed rescissions of more than \$1 billion in FY 2025 funding for global health. **Congress voted to amend the package, reducing that amount to \$500 million and exempting some program areas, including TB, from the rescission.**

### **The Trump Administration's Foreign Aid Review: Status of PEPFAR**

July 23, 2025

...*What to Watch*

- **...Funding/Budget Request:** The administration's FY 2026 budget request includes significant reductions in funding for global health, including a \$1.9 billion reduction for PEPFAR. Final appropriation amounts for FY 2026 will be determined by Congress. **The administration also submitted its first rescission package to Congress, including proposed rescissions of \$400 million in FY 2025 funding for PEPFAR. Congress voted to amend the package, exempting PEPFAR from the rescission.**

### **The Trump Administration's Foreign Aid Review: Status of U.S. Family Planning and Reproductive Health Efforts**

July 23, 2025

...*What to Watch:*

- **...Funding/Budget Request:** The administration's FY 2026 budget request includes significant reductions in funding for global health, and does not include funding for family planning. Final appropriation amounts for FY 2026 will be determined by Congress. **The administration also submitted its first rescission package to Congress, including proposed rescissions of more than \$1 billion in FY 2025 funding for global health. Congress voted to amend the package, reducing that amount to \$500 million, and while it exempted some program areas from the rescission, most or all of the funding to be rescinded will come from family planning.**
- *Policy restrictions:* The administration may seek to institute additional policy restrictions on other U.S.-funded global health and development programs regarding abortion and family planning services, such as a further expansion of the Mexico City Policy.

### **KFF Global Health Budget Summaries**

July 24, 2025

The House Committee on Appropriations approved the FY 2026 National Security, Department of State, and Related Programs (NSRP) appropriations bill and accompanying report on July 23, 2025. The NSRP bill includes funding for U.S. global health programs at the State Department through the Global Health Programs (GHP) account, which represents the bulk of global health assistance.

Global health funding in the bill totaled \$9.5 billion, a decrease of \$512 million (-5%) below the FY 2025 enacted level and \$5.7 billion (151%) above President Trump's FY 2026 request.<sup>[i]</sup> As compared to FY 2025 enacted levels, funding through the GHP account for the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) and family planning and reproductive health (FP/RH) declined, while all other areas either remained flat or increased slightly; funding for global health security was not specified.<sup>[ii]</sup>

The bill does not specify funding for the Health Reserve Fund, Global Health Workforce Initiative, or the Pan American Health Organization (PAHO), and explicitly prohibits funding for the United Nations Population Fund (UNFPA) and World Health Organization (WHO).<sup>[iii]</sup> The bill also eliminates funding for the International Organizations & Programs (IO&P) account, which has historically been the source of U.S. contributions to the United Nations Children’s Fund (UNICEF).<sup>[iv]</sup>

**Table: KFF Analysis of Global Health Funding in the FY 2026 House Appropriations Bill & Explanatory Statement**

Department / Agency / Area	FY25 CR <sup>i,ii</sup> (millions)	FY26 Request (millions)	FY26 House (millions)	Difference: FY26 House - FY25 CR	Difference: FY26 House - FY26 Request
<b>National Security, Department of State and Related Programs (NSRP) - Global Health Programs (GHP) Account<sup>iii</sup></b>					
HIV/AIDS (PEPFAR) <sup>iv</sup>	\$4,725.0	\$2,910.0	\$4,725.0	\$0 (0%)	\$1,815 (62.4%)
State Department	\$4,395.0	\$2,910.0	-	-	-
USAID	\$330.0	\$0.0	-	-	-
Global Fund <sup>v</sup>	\$1,650.0	vi	\$1,500.0	\$-150 (-9.1%)	-
Tuberculosis <sup>iv</sup>	\$394.5	\$178.0	\$394.5	\$0 (0%)	\$206.5 (116%)
Malaria (PMI)	\$795.0	\$424.0	\$800.0	\$5 (0.6%)	\$376 (88.7%)
Maternal & Child Health (MCH) <sup>iv</sup>	\$1,057.0	\$85.0	\$915.0	\$-142 (-13.4%)	\$830 (976.5%)
Global Health Programs (GHP) account	\$915.0	\$85.0	\$915.0	\$0 (0%)	\$830 (976.5%)
<i>Bilateral MCH</i>	\$615.0	\$85.0	\$615.0	\$0 (0%)	\$530 (623.5%)
<i>of which Polio</i>	\$85.0	\$85.0	\$85.0	\$0 (0%)	\$0 (0%)
<i>Gavi, the Vaccine Alliance</i>	\$300.0	\$0.0	\$300.0	\$0 (0%)	\$300 (N/A)
United Nations Children's Fund (UNICEF) - IO&P Account <sup>vii</sup>	\$142.0	\$0.0	vii	-	-

[Excerpt]

...

Vulnerable Children	\$31.5	\$0.0	\$32.5	\$1 (3.2%)	\$32.5 (N/A)
Neglected Tropical Diseases (NTDs)	\$114.5	\$0.0	\$114.5	\$0 (0%)	\$114.5 (N/A)
Global Health Security <sup>iv, ix</sup>	\$700.0	\$200.0	ix	-	-
<i>of which the Coalition for Epidemic Preparedness Innovations (CEPI)</i>	xii	-	xii	-	-
<i>of which Emergency Reserve Fund</i>	xiii	xiv	xv	-	-
Health Reserve Fund <sup>xvi</sup>	\$6.0	\$0.0	\$0.0	\$-6 (-100%)	\$0 (0%)
Global Health Worker Initiative <sup>xvii</sup>	\$10.0	\$0.0	\$0.0	\$-10 (-100%)	\$0 (0%)

.....  
 .....  
 .....

## Polio – PHEIC

### Polio this week

#### **Headlines** [Selected]

:: *Women health workers leading efforts to end polio in Pakistan*

Click [here](#) for a powerful message by WHO Eastern Mediterranean Regional Director Dr Hanan Balkhy, on the incredible work by women health workers to end polio in their communities, during a recent visit to Peshawar, Pakistan.

#### **Summary of new polioviruses this week, cases and positive environmental isolates:**

- Afghanistan: four WPV1-positive environmental samples
- Angola: one cVDPV2 case
- Cameroon: one cVDPV3 case
- Chad: one cVDPV2-positive environmental sample
- Papua New Guinea: ten cVDPV2-positive environmental samples
- Somalia: one cVDPV2-positive environmental sample
- Yemen: 22 cVDPV2 cases and 17 cVDPV2-positive environmental samples

.....  
 .....

## mPox – PHEIC

*No new digest content identified.*

.....  
.....

### ***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

.....  
.....

### **WHO & Regional Offices** [to 26 July 2025]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

24 July 2025 *News release*

#### **Timor-Leste certified malaria-free by WHO**

The World Health Organization (WHO) has certified Timor-Leste as malaria-free, a remarkable achievement for a country that prioritized the disease and embarked on a concerted, nation-wide response shortly after gaining independence in 2002.

"WHO congratulates the people and government of Timor-Leste on this significant milestone," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "Timor-Leste's success proves that malaria can be stopped in its tracks when strong political will, smart interventions, sustained domestic and external investment and dedicated health workers unite."

With today's announcement, a total of 47 countries and 1 territory have been certified as malaria-free by WHO...

21 July 2025 *News release*

#### **WHO operations compromised following attacks on warehouse and facility sheltering staff and families in Deir al Balah, Gaza**

WHO condemns in the strongest terms the attacks on a building housing WHO staff in Deir al Balah in Gaza, the mistreatment of those sheltering there, and the destruction of its main warehouse.

Following intensified hostilities in Deir al Balah after the latest evacuation order issued by Israeli military, the WHO staff residence was attacked three times today. Staff and their families, including children, were exposed to grave danger and traumatized after airstrikes caused a fire and significant damage. Israeli military entered the premises, forcing women and children to evacuate on foot toward Al-Mawasi amid active conflict. Male staff and family members were handcuffed, stripped, interrogated on the spot, and screened at gunpoint. Two WHO staff and two family members were detained. Three were later released, while one staff member remains in detention. Thirty-two people, including women and children, were collected and evacuated to the WHO office in a high-risk mission, once access became possible. The office itself is close to the evacuation zone and active conflict.

WHO demands continuous protection of its staff and the immediate release of the remaining detained staff member.

The latest evacuation order has affected several WHO premises. As the United Nations's (UN) lead health agency, WHO's operational presence in Gaza is now compromised, crippling efforts to sustain a collapsing health system and pushing survival further out of reach for more than two million people. Most of WHO's staff housing is now inaccessible...

.....

### **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region AFRO**

:: 21 July 2025

#### **[Advancing access to sexual and reproductive health services in South Sudan](#)**

### **WHO Region of the Americas PAHO**

:: 25 Jul 2025

#### **[PAHO and Resolve to Save Lives strengthen partnership to bolster epidemic preparedness across the Americas](#)**

Washington, D.C., 25 July 2025 — The Pan American Health Organization (PAHO) and Resolve to Save Lives have renewed their commitment to enhancing epidemic preparedness and response capacities throughout Latin America and the Caribbean. This strengthened collaboration follows the recent signing of a comprehensive Framework Agreement between...

:: 22 Jul 2025

#### **[PAHO Director and CARICOM Secretary-General sign 2025-2029 Joint Subregional cooperation strategy to advance health and equity in the Caribbean](#)**

Georgetown, Guyana, 22 July 2025 (PAHO) – The Joint Subregional Cooperation Strategy that will provide a coordinated framework for technical cooperation to address common public health challenges in the Caribbean was signed today by the Director of the Pan American Health Organization, Dr. Jarbas Barbosa, and Dr. Carla N. Barnett, Secretary-...

### **WHO South-East Asia Region SEARO**

*No new digest content identified.*

### **WHO European Region EURO**

*No new digest content identified.*

### **WHO Eastern Mediterranean Region EMRO**

#### **[WHO and Gavi support Pakistan's vaccinators with 800 motorbikes to access hard-to-reach areas in 65 priority districts](#)**

23 July 2025

### **WHO Western Pacific Region**

*No new digest content identified.*

.....

### **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

24 July 2025

#### **[Multi-country outbreak of cholera, external situation report #28 -24 July 2025](#)**

22 July 2025

#### **[Public Health Situation Analysis - Lebanon](#)**

*Overview*

Violations of the ceasefire have continued to rise across Lebanon, with attacks on Beirut's Southern Suburbs for the first time since the agreement came into effect in November 2024. June 2025 witnessed a pronounced intensification of Israeli military activity in Lebanon, characterized by an escalating use of airstrikes, drone warfare, and strategic signaling.

Lebanon's Ministry of Public Health (MoPH) reports that, since October 2023, over 17 300 people were injured and more than 4100 were killed in Lebanon (as of February 2025). According to OHCHR,

at least 71 civilians, including nine children and 14 women, have been killed in Lebanon during the ceasefire period...

Health services have been severely impacted, and the widespread damage to water, sanitation, and municipal infrastructure heightens the risk of disease outbreaks. The conflict, which impacted one in ten hospitals and killed 241 health workers while on duty, has taken a devastating toll on health infrastructure, resulting in overwhelming health needs. **Vaccination coverage has plummeted, leaving children vulnerable to preventable diseases**, while thousands of individuals with life-changing traumatic injuries urgently require reconstructive surgery. Additionally, after enduring over a year of profound suffering, addressing mental health needs is critical to fostering recovery and resilience.

.....

### **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

*Disease Outbreak News*

**[24 July 2025 | Rabies - Timor-Leste](#)**

.....

### **Weekly Epidemiological Record**

Vol. 100, Nos. 29/30, pp. 285–302 18 July 2025

<https://www.who.int/publications/journals/weekly-epidemiological-record>

:: WHO Alliance for the Global Elimination of Trachoma: progress report on elimination of trachoma, 2024–2025

*[Reviewed earlier]*

.....

### **New WHO Publications**

<https://www.who.int/publications>

*Selected*

25 July 2025

**[In vitro diagnostic tests for serious bacterial infection, including neonatal sepsis, among infants aged...](#)**

25 July 2025

**[Evaluation of the WHO Special Programme on Primary Health Care: Report](#)**

25 July 2025

**[Implementing the global framework on well-being at the country level](#)**

24 July 2025

**[WHO Malaria Policy Advisory Group: meeting report, 8-10 April 2025](#)**

22 July 2025

**[Research gaps and needs on Middle East respiratory syndrome coronavirus \(MERS-CoV\) and other emerging...](#)**

21 July 2025

**[Levels and trends in child malnutrition: UNICEF/WHO/World Bank Group joint child malnutrition estimates:...](#)**

.....  
.....

**Europe**

**European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

*Surveillance and monitoring*

**[Communicable disease threats report, 19–25 July 2025, week 30](#)**

25 Jul 2025

This issue of the CDTR covers the period 19–25 July 2025 and includes updates on respiratory viruses, avian influenza A(H9N2), avian influenza A(H5N1), cholera, Oropouche, mass gathering monitoring for the Jubilee of 2025 in Italy, mass gathering monitoring for UEFA Women's EURO 2025, Crimean-Congo haemorrhagic fever, West Nile Virus, dengue and chikungunya virus disease.

*Surveillance and monitoring*

**[Seasonal surveillance of dengue in the EU/EEA, weekly report](#)**

25 Jul 2025

This report gives an overview of the countries and areas where dengue cases – and their corresponding case numbers - have been reported to the European surveillance portal for infectious diseases (EpiPulse).

**European Medicines Agency [EMA]**

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

**[Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 21-24 July 2025](#)**

*13 new medicines recommended for approval; another 8 medicines recommended for extension of their therapeutic indications*

25 July 2025

... The committee recommended granting a marketing authorisation for **Yeytuo** (lenacapavir), for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually acquired human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents at high risk of becoming infected. This medicine will facilitate PrEP uptake and compliance because it only has to be administered twice a year via a subcutaneous injection. The committee simultaneously reviewed the medicine for the EU market, under the centralised procedure, and for non-EU countries, under the EU-Medicines for all (EU-M4all) programme that enables EMA to support global regulatory capacity building and contribute to the protection and promotion of public health beyond the EU. See more details in the news announcement in the grid below...

**[First reformulation of an inhaled medicine with environmentally friendly gas propellant](#)**

The new propellant in Trixeo Aerosphere and Riltrava Aerosphere has lower global warming potential

25 July 2025

**[New injection for easier prevention of HIV infection in the EU and worldwide](#)**

Injectable lenacapavir, administered twice yearly, is highly effective at preventing HIV

25 July 2025

### **Ixchig: temporary restriction on vaccinating people 65 years and older to be lifted**

Vaccine to be used only when there is a significant chikungunya risk and after careful consideration of the benefits and risks

25 July 2025

### **EMA Paediatric Committee elects Sabine Scherer as its new chair**

Sabine Scherer begins her three-year mandate in September 2025

24 July 2025

.....

.....

### **Africa CDC** [to 26 July 2025]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

### **Africa Sets Course to Strengthen and Harmonise Health Data Governance**

23 July 2025

*Stories*

### **Malaria Surge in Southern Africa**

23 July 2025

Malaria is on the rise in southern Africa, with several countries – including Botswana, eSwatini, Namibia and Zimbabwe – reporting new outbreaks, underscoring the ongoing challenges in eradicating the disease in Africa...

*Stories*

### **New Study Reveals Widespread Drug Resistance Across 14 African Countries**

23 July 2025

...The study, known as the Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP), is the largest of its kind ever conducted in Africa. It was led by a coalition including the Africa Centres for Disease Control and Prevention (Africa CDC), the African Society for Laboratory Medicine (ASLM), One Health Trust, and other regional partners.

Researchers reviewed more than 187,000 test results from 205 laboratories, collected between 2016 and 2019 across Burkina Faso, Eswatini, Ethiopia, Ghana, Kenya, Malawi, Mali, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe...

*Stories*

### **Africa CDC Set to Launch Groundbreaking Knowledge Management Portal**

23 July 2025

... A new initiative, soon to be launched by the Africa Centres for Disease Control and Prevention (Africa CDC), is set to enhance the management of knowledge on health issues and emerging diseases like mpox. This marks a significant step in transforming the continent's public health landscape. The knowledge management initiative will ensure that health knowledge is readily available, accessible, and translated into policies and practices to prevent and control diseases and strengthen the health system in Africa...

.....

### **China CDC+**

<http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 26 July 2025]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

**National Medical Products Administration – PRC** [to 26 July 2025]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

**China CDC**

**CCDC Weekly Reports: Current Volume (7)**

**2025-07-25 / No. 30**

[PDF of this issue](#)

- [Commentary: World Hepatitis Day 2025: Progress and Challenges in the Global Elimination of Viral Hepatitis](#)
- [Preplanned Studies: Evaluations of Community-based Healthcare Management for Patients with Chronic Viral Hepatitis — Shanghai Municipality, China, 2012–2023](#)
- [Preplanned Studies: Partner Tracing Survey and Phylogenetic Analysis Among Newly Diagnosed HIV-Positive MSM — Shenzhen City, Guangdong Province, China, 2019–2022](#)
- [Outbreak Reports: The First Imported Case of Zika Virus Infection — Shandong Province, China, 2025](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, June 2025\\*](#)

.....

.....

***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

***Organization Announcements***

**Paul G. Allen Frontiers Group** [to 26 July 2025]

<https://alleninstitute.org/news-press/>

*Recent News*

*Video*

**[Before the breakthrough: Why basic science matters](#)**

Jul 22, 2025

A look at how the Allen Institute uses basic science to drive discovery and future breakthroughs.

**BMGF - Gates Foundation** [to 26 July 2025]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

*No new digest content identified.*

**CARB-X** [to 26 July 2025]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**Chan Zuckerberg Initiative** [to 26 July 2025]

<https://chanzuckerberg.com/newsroom/>

*Newsroom*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 26 July 2025]

<http://cepi.net/>

*CEPI News, Blog*

*News*

**[New protein vaccine approach could enable faster responses to Disease X](#)**

The pioneering approach uses protein-tagging technology in nanoparticles that could also boost immune responses and allow for more targeted vaccine delivery.

23 Jul 2025

*News*

**[Fighting outbreaks with FEEVA: New project could support faster approvals of vaccines](#)**

22 Jul 2025

...FEEVA (a Framework for Evidence Evaluation in Vaccine Assessment) is a new collaborative project led by the [Kirby Institute](#) at UNSW Sydney and the [Australian Living Evidence Collaboration](#) (ALEC) at Monash University supported by up to US \$3m funding from global health organisations CEPI and Wellcome.

The first-of-its-kind initiative will work with immunologists, vaccine developers and regulators to explore how early evidence on a vaccine's efficacy could be reviewed by regulators alongside robust safety data to support potential early deployment in an outbreak...

*News*

**[R&D experts to create playbooks that map immune markers in deadly diseases](#)**

20 Jul 2025

**CIDRAP – Vaccine Integrity Project**

<https://www.cidrap.umn.edu/vaccine-integrity-project>

*News, Reports, Viewpoints*

*No new digest content identified.*

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 26 July 2025]

<https://cioms.ch/>

*News; Publications; Events*

**[CIOMS cumulative glossary \(version 2.3\) now available](#)**

The CIOMS cumulative glossary is an organized collection of the terms and definitions included in published CIOMS Working Group reports, with a focus on pharmacovigilance.

## **CIOMS Glossary of ICH Terms & Definitions**

A glossary of ICH terms and definitions has been compiled by CIOMS from across ICH Guidelines. For information on this helpful CIOMS initiative, please visit the CIOMS website, where the glossary is freely available for download, providing a useful resource for both CIOMS and ICH Stakeholders and Working Groups.

## **DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 26 July 2025]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

## **DNDI – Drugs for Neglected Diseases initiative** [to 26 July 2025]

<https://dndi.org/press/press-releases/>

*Press Releases*

*Press releases* 23 Jul 2025

**AN2 Therapeutics and DNDi collaborate on clinical development of promising new oral compound to treat chronic Chagas disease**

## **Duke Global Health Innovation Center** [to 26 July 2025]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

## **EDCTP** [to 26 July 2025]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

25 July 2025

**EDCTP Annual Report 2024: Achieving real impact**

## **Emory Vaccine Center** [to 26 July 2025]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

## **European Vaccine Initiative** [to 26 July 2025]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

## **Fondation Merieux** [to 26 July 2025]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gates Medical Research Institute** [to 26 July 2025]

<https://www.gatesmri.org/news>

*The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.*

*News: Articles and Publications*

*No new digest content identified.*

**Gavi** [to 26 July 2025]

<https://www.gavi.org/>

*Press Releases*

25 July 2025

**[Gavi Board focuses on priority health impact as guiding principle in a resource constrained world](#)**

**GE2P2 Global Foundation** [to 26 July 2025]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review - Current edition](#)

:: [Informed Consent: A Monthly Review – May 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 25 May 2025](#)

:: [Genomics :: Governance, Ethics, Policy, Practice – A Monthly Digest – May 2025](#)

**GHIT Fund** [to 26 July 2025]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 26 July 2025]

<https://www.theglobalfund.org/en/news/>

*News Releases*

24 July 2025

**[Global Fund Applauds Timor-Leste's Elimination of Malaria](#)**

Timor-Leste has officially been certified malaria-free by the World Health Organization (WHO), becoming the third country in the WHO South-East Asia Region to eliminate the disease. This certification confirms the successful interruption of indigenous...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 26 July 2025]

<https://www.glopid-r.org/>

*No new digest content identified.*

**Hilleman Laboratories** [to 26 July 2025]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 26 July 2025]

<https://www.hhmi.org/news>

*Press Room*

**'Prime Editing' Corrects Genetic Mutations Causing Rare Childhood Brain Disease**

July 21, 2025

**Human Immunome Project [nee Human Vaccines Project]** [to 26 July 2025]

<https://www.humanimmunomeproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 26 July 2025]

<https://www.iavi.org/>

*Press Releases, Features*

July 25, 2025

**IAS 2025 Kigali reaffirms what it will take to keep HIV progress from sliding back  
Science and equity must move together, supported by sustained funding, to keep the HIV  
response on track.**

**INSERM** [to 26 July 2025]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH [International Council for Harmonisation of Technical Requirements for  
Pharmaceuticals for Human Use]** [to 26 July 2025]

<https://www.ich.org/>

## News/Pubs/Press Releases [Selected]

Ongoing Public Consultations		^
>	M13B EWG	Bioequivalence for Immediate-Release Solid Oral Dosage Forms
>	Q1 EWG	Stability Testing of Drug Substances and Drug Products
>	M4Q(R2) EWG	Revision of M4Q(R1)
>	E21 EWG	Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials

<https://www.ich.org/page/public-consultations>

**ICRC** [to 26 July 2025]

<https://www.icrc.org/en/news>

News

[Israel and the occupied territories: ICRC president calls for urgent collective action by states to end abhorrent suffering in Gaza](#)

Statement 25-07-2025

[Nigeria: Hunger deepens as farmers in the conflict-affected northeast struggle to survive](#)

News release 21-07-2025

**IFFIm** [to 26 July 2025]

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

**IFRC** [to 26 July 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press releases

Press release 24/07/2025

[Red Cross Mobilises as Storms Slam the Philippines](#)

Press release 21/07/2025

[Afghanistan population movement: IFRC sounds alarm on severe funding gap](#)

**IPPS - International Pandemic Preparedness Secretariat** [to 26 July 2025]

<https://ippsecretariat.org/news/>

News

No new digest content identified.

**Institut Pasteur** [to 26 July 2025]

<https://www.pasteur.fr/en/press-area>

Press Documents

Press release 25.07.2025

[A human protein inherited from bacteria reveals an overlooked aspect of human immunity](#)

What if the study of bacteria could illuminate our understanding of human immunity? In recent years, scientists have.

**ISC / International Science Council** [to 26 July 2025]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

*No new digest content identified.*

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

*No new digest content identified.*

**IVAC** [to 26 July 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 26 July 2025]

<http://www.ivi.int/>

*IVI News & Announcements*

**[IVI opens Bhutan-IVI Collaborating Center](#)**

July 15, 2025 – On July 8, the Bhutan-IVI Collaborating Center was officially launched in Thimphu, Bhutan, marking a significant milestone in strengthening regional health research, pandemic preparedness, and capacity building in Asia.

**Johns Hopkins Center for Health Security** [to 26 July 2025]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 26 July 2025]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Nigeria*

**[Mobilisation is urgently needed to avoid further deaths from northern Nigeria malnutrition crisis](#)**

Press Release 25 Jul 2025

*Gaza-Israel war*

**[MSF finds one in four young children and pregnant women malnourished at Gaza facilities](#)**

Press Release 25 Jul 2025

*Syria*

**[MSF expands support to respond to people's unmet needs across Syria](#)**

Project Update 24 Jul 2025

*Yemen*

**[Measles threatens children's lives in Dhamar](#)**

Project Update 24 Jul 2025

*Democratic Republic of Congo*

**[MSF is the only international humanitarian organisation responding to people's growing needs in Walikal...](#)**

Press Release 24 Jul 2025

*Gaza-Israel war*

**[Premature babies fight for their lives in north Gaza](#)**

Voices from the Field 23 Jul 2025

*Gaza-Israel war*

**[As mass starvation spreads across Gaza, our colleagues and those we serve are wasting away](#)**

Statement 23 Jul 2025

*Guatemala*

**[MSF concludes project for migrants in Guatemala](#)**

Project Update 23 Jul 2025

*Papua New Guinea*

**[Supporting victims and survivors of violence in Papua New Guinea's Highlands](#)**

Project Update 22 Jul 2025

*Palestine*

**[Never-ending violence by Israeli settlers and military psychologically scars Palestinians in Hebron](#)**

Project Update 21 Jul 2025

**National Academy of Medicine** - USA [to 26 July 2025]

<https://nam.edu/programs/>

*No new digest content identified.*

**National Academies-Sciences-Engineering-Medicine [NASEM]**- USA [to 26 July 2025]

<https://www.nationalacademies.org/newsroom>

*News*

**[New Issue Paper: Identifying Gaps in Sexual Harassment Remediation Efforts in Higher Education](#)**

A new issue paper from the Action Collaborative on Preventing Sexual Harassment in Higher Education synthesizes the existing research on harms that survivors, accused individuals, and community members may experience and resulting institutional responses. The publication also identifies over 50 efforts that institutions are taking to repair those harms and identifies gaps that can benefit from further research.

Date - 2025-07-23

Type - Media Advisory

**PATH** [to 26 July 2025]

<https://www.path.org/media-center/>

*Newsroom [Selected]*

**[R&D experts to create playbooks that map immune markers in deadly diseases](#)**

July 21, 2025 by PATH

Oslo, Norway & Seattle, United States, July 21, 2025—The global health organisations CEPI and PATH are joining forces to create pivotal playbooks that map all available research into specific immune markers that indicate protection against target viruses with epidemic or pandemic potential.

Supported by US\$8 million in funding from CEPI, these research and development (R&D) manuals could hold important insights for scientists, vaccine developers and regulators to more quickly and easily determine whether a vaccine candidate will generate protective immunity against certain deadly pathogens. This includes viruses like monkeypox, Lassa, Zaire ebolavirus, Sudan ebolavirus, and Marburg...

**Sabin Vaccine Institute** [to 26 July 2025]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 26 July 2025]

<http://www.unaids.org/en>

*News, Stories, Updates*

21 July 2025

**[Funding cuts undermine community-led innovations in the Philippines](#)**

**UNICEF** [to 26 July 2025]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements [Selected]*

Statement 24 July 2025

**[Statement by UNICEF Regional Director for the Middle East and North Africa Edouard Beigbeder on the unconscionable deaths of children by starvation in the Gaza Strip](#)**

AMMAN, 24 July 2025 – , “Children in the Gaza Strip are starving to death. “Severe malnutrition is spreading among children faster than aid can reach them, and the world is watching it happen. Since April this year, the reported number of children who have died from malnutrition has jumped from 52 to 80 - a stagge...

*Statement 23 July 2025*

**[Statement by UNICEF Regional Director, Edouard Beigbeder, on the impact of hostilities on children in Syria](#)**

AMMAN, 23 July 2025 -, “The recent violence in Syria, including in As-Sweida, Damascus, and Dar’a, has impacted children's lives and wellbeing. “Several children are reported to have been killed and maimed. This is heartbreaking and unacceptable. Our deepest condolences go to their loved ones. “UNICEF is concerned about the psychosocial wellbeing of children and their...

**Unitaid** [to 26 July 2025]

<https://unitaid.org/>

*News*

*No new digest content identified.*

**Vaccine Equity Cooperative [nee Initiative]** [to 26 July 2025]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccine Confidence Project** [to 26 July 2025]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 26 July 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

- [Families: subscribe to Parents PACK](#)
- [Professionals: subscribe to Vaccine Update](#)
- [Educators: subscribe to The VMP Chronicle](#)
- [Science & history enthusiasts: subscribe to The Hilleman Chronicle](#)

**Wellcome Trust** [to 26 July 2025]

<https://wellcome.org/news/all>

*News. Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 26 July 2025]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**World Bank** [to 26 July 2025]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 26 July 2025]

<https://www.wfpha.org/>

*Blog, Events*

*No new digest content identified.*

**World Medical Association [WMA]** [to 26 July 2025]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

[\*\*The World Medical Association Expresses Deep Concern Over Humanitarian Crisis in Gaza\*\*](#)

25th July 2025

The World Medical Association (WMA) expresses its deep concern over the escalating humanitarian crisis in Gaza, which continues to put civilian lives and healthcare services at grave risk.

There is a dire shortage of safe shelter across the region. Food, clean water, and essential medicines are critically lacking, placing vulnerable populations in immediate danger. The WMA is alarmed by increasing reports of civilian casualties caused by weapons fire at or near humanitarian aid distribution centres.

The WMA urges all parties to exercise the utmost restraint in and around aid centres and civilian shelters to protect lives and uphold international humanitarian norms.

Of particular concern are the dangerous conditions under which doctors, nurses, and other medical staff are being forced to work. Many are operating under life-threatening circumstances, with insufficient resources and limited protection.

The WMA calls for the strict adherence to international humanitarian law by all parties involved in the conflict. This includes the immediate release of hostages and the facilitation of humanitarian aid, ensuring dignified access to food, water, and medicines.

The WMA reaffirms its hope for an immediate end to the hostilities and urges all parties to commit to a path toward lasting peace.

#### **World Organisation for Animal Health [OIE]** [to 26 July 2025]

<https://www.oie.int/>

*Press Releases, Statements*

*No new digest content identified.*

.....

.....

#### **ARM [Alliance for Regenerative Medicine]** [to 26 July 2025]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest announcements identified.*

#### **BIO** [to 26 July 2025]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest announcements identified.*

#### **DCVMN – Developing Country Vaccine Manufacturers Network** [to 26 July 2025]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest announcements identified.*

#### **ICBA – International Council of Biotechnology Associations** [to 26 July 2025]

<https://internationalbiotech.org/news/>

*News*

*No new digest announcements identified.*

#### **IFPMA** [to 26 July 2025]

<https://ifpma.org/>  
*News, Statements [Selected]*  
*No new digest announcements identified.*

**International Alliance of Patients' Organizations – IAPO** [to 26 July 2025]

<https://www.iapo.org.uk/news>  
*Press and media [Selected]*  
*No new digest announcements identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>  
*News*  
*No new digest announcements identified.*

**PhRMA** [to 26 July 2025]

<http://www.phrma.org/>  
*Press Releases*  
*No new digest announcements identified.*

.....  
.....

***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

*We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.*

**AstraZeneca**

*Press Releases - No new digest announcements identified.*

**Bavarian Nordic**

*Latest News*

July 22, 2025

[\*\*Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine\*\*](#)

**BioCubaFarma – Cuba**

*Últimas Noticias - No new digest announcements identified.*

**Biological E**

*News - No new digest announcements identified.*

**BioNTech**

*Press Releases*

25 July 2025

[\*\*Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union\*\*](#)

*Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants<sup>1</sup> – compared to 2024-2025 COVID-19 vaccine formulations*

**Boehringer**

Press Releases - No new digest announcements identified.

**CanSinoBIO**

News - Website not responding at inquiry.

**CIGB**

Latest News - No new digest announcements identified.

**CinnaGen**

Recent News - No new digest announcements identified.

**Clover Biopharmaceuticals – China**

News - No new digest announcements identified.

**Curevac**

News - No new digest announcements identified.

**Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

**GSK**

Press releases for media - No new digest announcements identified.

**EuBiologics, S Korea**

News - No new digest announcements identified.

**IMBCAMS, China**

Home - Website not responding at inquiry.

**JNJ Innovative Medicine [Janssen]**

Press Releases - No new digest announcements identified.

**Merck**

News releases - No new digest announcements identified.

**Nanogen**

News - No new digest announcements identified.

**Novartis**

News - No new digest announcements identified.

**Novavax**

Press Releases

Jul 24, 2025 Press release

**[Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study](#)**

:: Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration

:: Potential for single intranasal or intramuscular dose could differentiate Novavax's vaccine as part of pandemic emergency preparedness efforts

## **Pfizer**

[Recent Press Releases](#)

### **[Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union](#)**

07.25.2025

:: Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants<sup>1</sup> – compared to 2024-2025 COVID-19 vaccine formulations

:: Upon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and older

## **R-Pharm**

<https://rpharm-us.com/index.php>

*[No news or media page identified]*

## **Sanofi Pasteur**

[Press Releases](#)

July 22, 2025

### **[Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline](#)**

...The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio's 'Molecular Clamp' technology.

The vaccine candidate complements Sanofi's position in the respiratory vaccines space where the company is present in flu and RSV prevention. It allows Sanofi to offer increased physician and patient choice in RSV and hMPV by adding a non-mRNA vaccine to its pipeline...

## **Serum Institute**

[News & Announcements](#) - *No new digest announcements identified.*

## **Sinopharm/WIBPBIBP**

[News](#) - *No new digest announcements identified.*

## **Sinovac**

[Press Releases](#) - *No new digest announcements identified.*

## **SK Biosciences**

[Press Releases](#)

### **[SK bioscience Releases 2025 ESG Report](#)**

Company establishes integrated ESG management system by consolidating ESG information from its subsi...

2025.07.22

## **Takeda**

[Newsroom](#) - *No new digest announcements identified.*

## **Valneva**

[Press Releases](#) - *No new digest announcements identified.*

## **Vector State Research Centre of Virology and Biotechnology**

[Home](#) - *[Website not responding [404 error]]*

## **WestVac Biopharma**

Media - No new digest announcements identified.

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....  
.....

## ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

## ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

## **AJOB Empirical Bioethics**

Volume 16, 2025 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

## **AMA Journal of Ethics**

Volume 27, Number 7: E479-540

<https://journalofethics.ama-assn.org/issue/rural-us-emergency-medical-services>

### **Rural US Emergency Medical Services**

Emergency medical services (EMS) are the most immediate health care resource for many US residents living in rural areas. We all rely on EMS to coordinate deployment of networks of transporters, first-responders, basic and intermediate emergency medical technicians, paramedics, and medical directors. These clinicians bring professional skill sets and scopes of practice to their crews when our health needs are urgent. Yet, low call volume in rural areas hinders responders' exposure to real-life procedures and undermines reimbursement for services rendered, so many rural EMS programs must depend—and perhaps overly rely—on volunteers. Air transport and telehealth help some rural US residents overcome some proximity demands but are imperfect workarounds for meeting critical vulnerabilities and do not substantially mitigate rural/urban emergent care access inequity. This theme issue explores rural EMS as a source of clinical, legal, and policy-level questions neglected in health care ethics, policy, and equity discussions.

**American Journal of Human Genetics**

Jul 03, 2025 Volume 112 Issue 7 p1497-1732

<https://www.cell.com/ajhg/current>

***This month in The Journal***

Alyson B. Barnes, Sara B. Cullinan

Newborn screening (NBS) contributes to reduced newborn morbidity and mortality globally. While reducing morbidity and mortality is already a public health success, the need for expanded and more widely adopted NBS initiatives is emphasized by the United Nations' goal to end preventable deaths of newborns and children under five years old by 2030. Incorporating genomic sequencing into NBS programs would enable earlier identification of a wide range of conditions, pushing us closer to this goal. Indeed, the value of including genomic sequencing in NBS programs is well recognized in the medical community, but an important component of ensuring successful implementation of such programs is understanding public values.

**American Journal of Infection Control**

August 2025 Volume 53 Issue 8 p809-918

<http://www.ajicjournal.org/current>

[Reviewed earlier]

**American Journal of Preventive Medicine**

August 2025 Volume 69 Issue 2

<https://www.ajpmonline.org/current>

[New issue; No digest content identified]

**American Journal of Public Health**

August 2025 115(8)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

**American Journal of Tropical Medicine and Hygiene**

Volume 113 (2025): Issue 1 (Jul 2025)

<https://www.ajtmh.org/view/journals/tpmd/113/1/tpmd.113.issue-1.xml>

[Reviewed earlier]

**Annals of Internal Medicine**

July 2025 Volume 178, Issue 7

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 345 August 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/345/suppl/C>

[Reviewed earlier]

## **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 26 July 2025)

### **[The cost of delivering COVID-19 vaccines in four districts in Malawi](#)**

*While COVID-19 vaccines became available in late 2020, low-income countries (LICs) faced challenging COVID-19 vaccine distribution efforts in terms of both a delayed and scarce vaccine supply and barriers reac...*

Authors: Anika Ruisch, Simon Ntopi, Ishani Mathur, Maeve Conlin, Anna McCaffrey, Damian G. Walker and Christian Suharlim

Citation: *Cost Effectiveness and Resource Allocation* 2025 23:36

Content type: Research Published on: 22 July 2025

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 26 July 2025)

[No new digest content identified]

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 26 July 2025)

[No new digest content identified]

## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 26 July 2025)

[No new digest content identified]

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 26 July 2025)

[No new digest content identified]

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 26 July 2025)

No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 26 July 2025)

### **[Structural equation modeling of factors influencing childhood vaccination in Saudi Arabia](#)**

*Vaccines are a global health success story, saving millions of lives each year. However, barriers to acceptance, such as misinformation, safety concerns, and trust issues, persist among parents. This study aim...*

Authors: Fatimah O. Hobani, Abeer K. Alharthi and Manal F. Alharbi

Citation: BMC Public Health 2025 25:2548  
Content type: Research Published on: 25 July 2025

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 26 July 2025)

[No new digest content identified]

### **BMJ Evidence-Based Medicine**

August 2025 - Volume 30 - 4

<https://ebm.bmj.com/content/30/4>

[New issue; No digest content identified]

### **BMJ Global Health**

July 2025 - Volume 10 - 7

<https://gh.bmj.com/content/10/7>

[Reviewed earlier]

### **Bulletin of the Atomic Scientists**

DIGITAL MAGAZINE - May 2025

<https://thebulletin.org/magazine/2025-03/>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 103, Number 7, July 2025, 413-464

<https://www.who.int/publications/journals/bulletin/>

[Reviewed earlier]

### **Cell**

Jul 24, 2025 Volume 188 Issue 15 p3917-4172

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

### **Cell and Gene Therapy Insights**

May 2025 Issue Volume 11 Issue 4

<https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4>

[Reviewed earlier]

### **Child Care, Health and Development**

Volume 51, Issue 4 July 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 118, Issue 1 Pages: 1-271 July 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

### **Clinical Therapeutics**

July 2025 Volume 47 Issue 7 p463-532

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

### **Clinical Trials**

Volume 22 Issue 3, June 2025

<https://journals.sagepub.com/toc/ctja/22/3>

*Articles*

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 26 July 2025]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 155 August 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/155/suppl/C>

[New issue; No digest content identified]

### **The CRISPR Journal**

Volume 8, Issue 3 / June 2025

<https://www.liebertpub.com/toc/crispr/8/3>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 41, Issue 3 2025

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

August 2025 - Volume 38 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

### **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 26 July 2025]

[No new digest content identified]

### **Cytotherapy**

August 2025 Volume 27 Issue 8 p885-1030

<https://www.isct-cytotherapy.org/current>

*Editorial*

#### **[International Call for a 10-Year Moratorium on Heritable Human Genome Editing](#)**

A multi-stakeholder initiative to ensure safe and responsible use of genetic technologies May 2025

David Barrett, Paula Cannon, Miguel Forte, Tim Hunt, Queenie Jang, Devyn Smith

Published online: May 21, 2025

p885-887

*Committee Statement*

#### **[Immune Monitoring after Cell Therapy and Hematopoietic Cell Transplantation: Guidelines by the ISCT Stem Cell Engineering Committee](#)**

Linda Oppizzi, et al.

Published online: May 05, 2025

p888-902

#### **[Artificial intelligence, machine learning, and digitalization systems in the cell and gene therapy sector: a guidance document from the ISCT industry committees](#)**

Vincenzo Di Cerbo, et al.

Published online: May 22, 2025

p903-909

### **Developing World Bioethics**

Volume 25, Issue 2 Pages: 81-163 June 2025

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

### **Development in Practice**

Volume 35, Issue 4, 2025

<https://www.tandfonline.com/toc/cdip20/35/4?nav=tocList>

[Reviewed earlier]

### **Development Policy Review**

Volume 43, Issue 4 July 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

## **Disasters**

Volume 49, Issue 3 July 2025

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

## **eBioMedicine**

Volume 117 July 2025

<https://www.sciencedirect.com/journal/ebiomedicine/vol/117/suppl/C>

[Reviewed earlier]

## **EMBO Reports**

Volume 26 Issue 13 8 July 2025

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

## **Emerging Infectious Diseases**

Volume 31, Number 7—July 2025

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

## **Epidemics**

Volume 51 June 2025

<https://www.sciencedirect.com/journal/epidemics/vol/51/suppl/C>

[Reviewed earlier]

## **Epidemiology and Infection**

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

## **Ethics & Human Research**

Volume 47, Issue 3, Pages: 1-45, May–June 2025

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Undue inducement :: Deception in research***

[Reviewed earlier]

## **Ethics & International Affairs**

Volume 39 - Issue 1 - Spring 2025

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[New issue; No digest content identified]

### **Ethics, Medicine and Public Health**

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 35, Issue 3, June 2025

<https://academic.oup.com/eurpub/issue/35/3>

[Reviewed earlier]

### **Expert Review of Vaccines**

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

### **Foreign Affairs**

July/August 2025 Volume 104, Number 4

<https://www.foreignaffairs.com/issues/2025/104/4>

[Reviewed earlier]

### **Forum for Development Studies**

Volume 52, 2025 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

***The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities***

[Reviewed earlier]

### **Frontiers in Genetics**

<https://www.frontiersin.org/journals/genetics>

[Accessed 26 July 2025]

[No new digest content identified]

### **Frontiers in Genome Editing**

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 26 July 2025]

*Editorial*

Accepted on 25 Jul 2025

**[Editorial: Gene Editing to achieve Zero Hunger](#)**

Shakeel Ahmad, et al.

### **Frontiers in Medicine**

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 26 July 2025]

[No new digest content identified]

### **Gene Therapy – Nature**

Volume 32 Issue 3, May 2025

<https://www.nature.com/gt/volumes/32/issues/3>

[Reviewed earlier]

### **Genetics in Medicines**

Volume 27, Issue 6 June 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/65>

[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 26 July 2025]

[No new digest content identified]

### **Global Health Action**

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 26 July 2025]

[No new digest content identified]

### **Global Public Health**

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 26 July 2025]

[No new digest content identified]

### **Health and Human Rights**

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>

***Special Section: Distress Migration and the Right to Health***

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 20 - Issue 1 - January 2025

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

### **Health Policy and Planning**

Volume 40, Issue 5 June 2025

<https://academic.oup.com/heapol/issue/40/5>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 26 July 2025]

[No new digest content identified]

### **Human Gene Therapy**

Volume 36, Issue 13-14 / July 2025

<https://www.liebertpub.com/toc/hum/36/13-14>

[Reviewed earlier]

### **Humanitarian Practice Network**

<https://odihpn.org/>

[Accessed 26 July 2025]

*Featured Publications*

[No new digest content identified]

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 21 Issue 1, 2025

<https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList>

*Selected Content*

[Reviewed earlier]

### **Immunity**

Jul 08, 2025 Volume 58 Issue 7 p1615-1870

<https://www.cell.com/immunity/current>

[New issue; No digest content identified]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 26 July 2025]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content/>

[Accessed 26 July 2025]

[No new digest content identified]

### **International Health**

Volume 17, Issue 4, July 2025

<https://academic.oup.com/inthealth/issue/17/4>

[Reviewed earlier]

### **International Human Rights Law Review**

Volume 14 (2025): Issue 1 (Jun 2025)

<https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-1.xml>

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol. 12 No. 5 (2025): May 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/124>

[Reviewed earlier]

### **International Journal of Epidemiology**

Volume 54, Issue 3, June 2025

<https://academic.oup.com/ije/issue/54/3>

[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 18 Issue 2 2025

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/18/iss/2>

*Table of contents*

[Reviewed earlier]

### **JAMA**

July 22/29, 2025, Vol 334, No. 4, Pages 287-372

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

### **JAMA Health Forum**

July 2025, Vol 6, No. 7

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

### **JAMA Pediatrics**

July 2025, Vol 179, No. 7, Pages 691-810

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[New issue; No digest content identified]

### **JBİ Evidence Synthesis**

July 2025 - Volume 23 - Issue 7

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Adolescent Health**

July 2025 Volume 77 Issue 1 p1-172

<https://www.jahonline.org/current>

[Reviewed earlier]

### **Journal of Artificial Intelligence Research**

Vol. 83 (2025)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

### **Journal of Bioethical Inquiry**

Volume 22, Issue 1 March 2025

<https://link.springer.com/journal/11673/volumes-and-issues/22-1>

[Reviewed earlier]

### **Journal of Community Health**

Volume 50, Issue 3 June 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-3>

[Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 176 September 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/176/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 20 Issue 3, July 2025

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

July 2025 - Volume 79 - 7

<https://jech.bmj.com/content/79/6>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 18, Issue 2 June 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 21, Issue 1 (2025)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 36, Number 2, May 2025

<https://muse.jhu.edu/issue/54734>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 27, Issue 3 June 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-3>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 23, Issue 2 (2025)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of International Development**

Volume 37, Issue 5 Pages: 1-1193 July 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

**Journal of Medical Ethics**

July 2025 - Volume 51 - 7  
<http://jme.bmj.com/content/current>  
[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 12, Issue 3 (2025)  
<https://institutionalrepository.aah.org/jpcrr/>  
[Reviewed earlier]

**The Journal of Pediatrics**

Volume 282 July 2025  
<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/282/suppl/C>  
[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

Volume 18, 2025 Issue 1  
<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>  
[Reviewed earlier]

**Journal of Public Health Management & Practice**

July/August 2025 - Volume 31 - Issue 4  
<https://journals.lww.com/jphmp/pages/currenttoc.aspx>  
[Reviewed earlier]

**Journal of Public Health Policy**

Volume 46, Issue 2 June 2025  
<https://link.springer.com/journal/41271/volumes-and-issues/46-2>  
[Reviewed earlier]

**Journal of the Royal Society – Interface**

July 2025 Volume 22 Issue 228  
<https://royalsocietypublishing.org/toc/rsif/current>  
[Reviewed earlier]

**Journal of Travel Medicine**

Volume 32, Issue 5, July 2025  
<https://academic.oup.com/jtm/issue>  
[Reviewed earlier]

**Journal of Virology**

Volume 99 • Number 6 • June 2025  
<http://jvi.asm.org/content/current>  
[Reviewed earlier]

## **The Lancet**

Jul 26, 2025 Volume 406 Number 10501 p307-416

<https://www.thelancet.com/journals/lancet/issue/current>

### *Articles*

## **Tracking development assistance for health, 1990–2030: historical trends, recent cuts, and outlook**

Angela E Apeagyei, et al.

### *Summary*

### *Background*

Development assistance for health (DAH) rose to its highest levels during the COVID-19 pandemic but has since reduced amid rising global economic uncertainty and competing fiscal demands. In early 2025, major donors including the USA and the UK announced substantial reductions in aid, prompting concerns about the future of health financing in middle-income and low-income countries. To date, no comprehensive assessment has quantified the effects of these announced cuts on overall DAH levels or its future trajectories.

### *Methods*

We estimated DAH from 1990 to 2030, drawing from a wide range of data sources including the Organisation for Economic Co-operation and Development Creditor Reporting System database, online databases of agencies such as The Global Fund to Fight AIDS, Tuberculosis and Malaria and the Global Alliance for Vaccines and Immunization (Gavi), and financial reports from private philanthropies and non-governmental organisations. Disbursements were categorised by source, disbursing agency, health focus area, and recipient country using standardised keyword tagging methods developed over 15 years of Institute For Health Metrics and Evaluation Financing Global Health reports. For 2025, we incorporated budget cuts announced by major donors to develop preliminary estimates. Forecasts to 2030 used donor-specific funding targets and linear regression models. Additional refinements for this iteration of our DAH tracking included expanded donor coverage and disaggregation of health areas for additional disbursing entities.

### *Findings*

DAH peaked at US\$80·3 billion in 2021 and fell to \$49·6 billion in 2024. In 2025, announced budget cuts—particularly reductions in US bilateral aid—are expected to contribute to further declines in global DAH to \$38·4 billion, amounts last seen in 2009. Key global health institutions (eg, Foreign, Commonwealth & Development Office and US Agency for International Development and Agence Française) providing DAH for key infectious diseases and childhood vaccines will contract their own disbursements. Because these key multilateral development banks have been protected from the major funding cuts, the World Bank has increased its relative share of total DAH disbursements. Forecasts indicate continued stagnation in DAH until 2030 under current policies, reaching \$36·2 billion in 2030. Our sensitivity analyses suggest that our estimate for 2025 could range from \$36·8 billion in a pessimistic scenario to \$40·0 billion in an optimistic scenario, based on changes in US cuts. Similarly, in the next 5 years, total DAH is expected to reach \$37·8 billion in 2030 under a positive scenario for US contribution and \$34·5 billion under a negative scenario for US contribution.

### *Interpretation*

The global health financing landscape is entering a period of sustained cuts. Major reductions in DAH, particularly from historically leading donors, threaten to widen health disparities unless mitigated by increased domestic resource mobilisation or alternative financing mechanisms. This study highlights the urgent need for greater efficiency, strategic reprioritisation, and strengthened fiscal resilience in recipient countries to safeguard the substantial global health gains of the previous three decades.

### *Funding*

Gates Foundation.

Aug 2025 Volume 9 Number 8 p519-612, e16  
<https://www.thelancet.com/journals/lanchi/issue/current>  
[Reviewed earlier]

### **Lancet Digital Health**

Jun 2025 Volume 7 Number 6  
<https://www.thelancet.com/journals/landig/issue/current>  
[Reviewed earlier]

### **Lancet Global Health**

Jul 2025 Volume 13 Number 7 e1151-e1326  
<https://www.thelancet.com/journals/langlo/issue/current>  
[Reviewed earlier]

### **Lancet Infectious Diseases**

Jun 2025 Volume 25 Number 6 p595-700, e316-e369  
<https://www.thelancet.com/journals/laninf/issue/current>  
[Reviewed earlier]

### **Lancet Public Health**

Jul 2025 Volume 10 Number 7 e537-e639  
<https://www.thelancet.com/journals/lanpub/issue/current>  
[New issue; No digest content identified]

### **Lancet Respiratory Medicine**

Jul 2025 Volume 13 Number 7 p569-654, e33-e37  
<https://www.thelancet.com/journals/lanres/issue/current>  
[New issue; No digest content identified]

### **Maternal and Child Health Journal**

Volume 29, Issue 6 June 2025  
<https://link.springer.com/journal/10995/volumes-and-issues/29-6>  
[Reviewed earlier]

### **Medical Decision Making (MDM)**

Volume 45 Issue 5, July 2025  
<http://mdm.sagepub.com/content/current>  
[Reviewed earlier]

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*  
Volume 103, Issue 2 Pages: 243-637 June 2025  
<https://onlinelibrary.wiley.com/toc/14680009/current>  
[Reviewed earlier]

## **Molecular Therapy**

Jul 02, 2025 Volume 33 Issue 7 p2951-3452  
<https://www.cell.com/molecular-therapy/current>  
[Reviewed earlier]

## **Nature**

Volume 643 Issue 8073, 24 July 2025  
<https://www.nature.com/nature/volumes/641/issues/8073>  
*Editorial* 22 Jul 2025

### **[Help save 2 million lives: close the vaccine funding gap](#)**

*Gavi, the vaccine provider for the world's poorest people, needs an extra US\$3 billion to protect infants and other vulnerable groups. More donors must step up.*

## **Nature Biotechnology**

Volume 43 Issue 7, July 2025  
<https://www.nature.com/nbt/volumes/43/issues/7>  
[Reviewed earlier]

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>  
(Accessed 26 July 2025)  
[Reviewed earlier]

## **Nature Genetics**

Volume 57 Issue 7, July 2025  
<https://www.nature.com/ng/volumes/57/issues/7>  
[Reviewed earlier]

## **Nature Human Behaviour**

Volume 9 Issue 6, June 2025  
<https://www.nature.com/nathumbehav/volumes/9/issues/6>  
[Reviewed earlier]

## **Nature Medicine**

Volume 31 Issue 7, July 2025  
<https://www.nature.com/nm/volumes/31/issues/7>  
*Article Open* Access 10 Jun 2025

### **[Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns](#)**

Estimates of chikungunya virus prevalence across 180 countries and territories show that Southeast Asia, Africa and the Americas carry the most substantive burden, which would require reactive vaccine campaigns against new outbreaks and routine immunization in heavily endemic areas to reduce transmission.

Gabriel Ribeiro dos Santos, Fariha Jawed, Henrik Salje

### **Nature Reviews Drug Discovery**

Volume 24 Issue 7, July 2025

<https://www.nature.com/nrd/volumes/24/issues/7>

[Reviewed earlier]

### **Nature Reviews Genetics**

Volume 26 Issue 7, July 2025

<https://www.nature.com/nrg/volumes/26/issues/7>

[Reviewed earlier]

### **Nature Reviews Immunology**

Volume 25 Issue 6, June 2025

<https://www.nature.com/nri/volumes/25/issues/6>

[Reviewed earlier]

### **New England Journal of Medicine**

Volume 393 No. 4 July 24, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

#### **The Promise of Real-World Data for Research — What Are We Missing?**

A.B. Abbasi , L.H. Curtis , and R.M. Califf

The increasing availability of electronic health records (EHRs) and other sources of real-world data (RWD) could accelerate clinical research by dramatically reducing the cost of generating data and enabling information from medical encounters to be deployed for research and continuous learning. But although 96% of U.S. hospitals have adopted EHRs, according to federal data, these systems were designed to document individual episodes of care and facilitate the highest possible payment for that care, not to support clinical research. Data that aren't required for reimbursement are frequently of low quality and not comprehensive, and many important exposures and outcomes aren't reliably recorded.

These limitations directly affect the ability of real-world evidence (RWE), derived from RWD, to answer important questions faced by clinicians, patients, and policymakers. Observational studies that use RWD can yield important insights, but establishing causality is difficult given the potential for confounding, inadequate documentation of risk factors, and incomplete capture of critical outcomes, such as death. RWD are also of limited utility for most interventional trials, which remain dependent on error-prone, expensive, and labor-intensive manual data collection. These challenges are especially salient given the current administration's promotion of using RWD to help accelerate research on chronic disease.

During our recent federal service, we developed policies aimed at increasing the availability of RWD and their utility for evidence generation.<sup>1</sup> Although progress has been made, various challenges continue to impede the utilization of RWD for accelerating clinical research. Several approaches could permit use of routinely generated health data to develop evidence supporting clinical and policy decisions that could improve the health and longevity of people in the United States (see [table](#))...

Approach	Suggested Policies
Improve data capture at the source	Strengthen programs that reward clinicians and health care organizations for collecting high-quality data at the point of care, such as the CMS coverage with evidence development program Invest in using AI, including large language models, to improve data capture at the point of care
Enable access to longitudinal, whole-person data	Modify TEFCA to allow health data exchange for research Implement and fund a national all-payer claims database Reduce the cost and increase the timeliness of mortality data in the National Death Index Invest in organizations that can coordinate linkages among data sources and make data available for various study types, including interventional trials
Improve regulatory practices	Ensure that FDA reviewers and inspectors receive adequate training on uses of real-world data in regulatory applications Fund regulatory science to develop new methods for regulatory review, including safe uses of AI tools Develop a more adaptable federal framework for ethical oversight and informed consent in clinical research Define research risks as the incremental risks associated with research participation relative to receiving the standard of care

☆ AI denotes artificial intelligence, CMS Centers for Medicare and Medicaid Services, FDA Food and Drug Administration, and TEFCA Trusted Exchange Framework and Common Agreement.

## **Ivermectin to Control Malaria — A Cluster-Randomized Trial**

Authors: Carlos Chaccour, M.D., Ph.D. <https://orcid.org/0000-0001-9812-050X>, Marta Maia, D.V.M., Ph.D., Mercy Kariuki, M.Sc., Paula Ruiz-Castillo, Ph.D., Caroline Wanjiku, Ph.D., Lydia Kasiwa, B.Sc., Aurelia Brazeal, M.D., +40 , and N. Regina Rabinovich, M.D.,

### *Abstract*

#### Background

Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors. Whether mass administration of ivermectin, a broad-spectrum antiparasitic drug that also kills mosquitoes feeding on treated persons, can reduce malaria transmission is unclear.

#### Methods

We conducted a cluster-randomized trial in Kwale, a county in coastal Kenya in which malaria is highly endemic and coverage and use of insecticide-treated nets are high. Clusters of household areas were randomly assigned in a 1:1 ratio to receive mass administration of ivermectin (400 µg per kilogram of body weight) or albendazole (400 mg, active control) once a month for 3 consecutive months at the beginning of the “short rains” season. Children 5 to 15 years of age were tested for malaria infection monthly for 6 months after the first round of treatment. The two primary outcomes were the cumulative incidence of malaria infection (assessed among children 5 to 15 years of age) and of adverse events (assessed among all eligible participants). Analyses were performed with generalized estimating equations in accordance with the intention-to-treat principle.

#### Results

A total of 84 clusters comprising 28,932 eligible participants underwent randomization. The baseline characteristics of the participants were similar in the trial groups. Six months after the first round of treatment, the incidence of malaria infection was 2.20 per child-year at risk in the ivermectin group and 2.66 per child-year at risk in the albendazole group; the adjusted incidence rate ratio (ivermectin vs. albendazole) was 0.74 (95% confidence interval [CI], 0.58 to 0.95, P=0.02). The incidence of serious adverse events per 100 treatments did not differ significantly between the trial groups (incidence rate ratio, 0.63; 95% CI, 0.21 to 1.91).

#### Conclusions

Among children 5 to 15 years of age who were living in an area with high coverage and use of bed nets, ivermectin, administered once a month for 3 consecutive months, resulted in a 26% lower incidence of malaria infection than albendazole. No safety concerns were identified. (Funded by Unitaid; BOHEMIA ClinicalTrials.gov number, [NCT04966702](#); Pan African Clinical Trial Registry number, PACTR202106695877303.)

*Editorials*

**Ivermectin against Malaria — Good News in Bad Times**

R.W. Steketee

**NEJM Evidence**

Volume 4 No. 7 July 2025

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[Reviewed earlier]

**njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 26 July 2025]

[No new digest content identified]

**Pediatrics**

Volume 156, Issue 1 July 2025

<https://publications.aap.org/pediatrics/issue/156/1>

[Reviewed earlier]

**PharmacoEconomics**

Volume 43, Issue 8 August 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-8>

[Reviewed earlier]

**PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 26 July 2025)

[No new digest content identified]

**PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 26 July 2025)

[No new digest content identified]

**PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 26 July 2025)

**Knowledge, attitudes and acceptance of COVID-19 vaccine among pregnant women in Mbeya Region**

Revocatus Lawrence Kabanga, Vincent John Chambo, Rebecca Mokeha

Research Article | published 24 Jul 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004408>

### **PLoS Medicine**

<https://journals.plos.org/plosmedicine/>

(Accessed 26 July 2025)

#### **[The potential global health impact and cost-effectiveness of next-generation influenza vaccines: A modelling analysis](#)**

Lucy Goodfellow, Simon R Procter, Mihaly Koltai, Naomi R. Waterlow, Johnny A. N. Filipe, Carlos K. H. Wong, Edwin van Leeuwen, Rosalind M. Eggo, Mark Jit, WHO Technical Advisory Group for the Full Value of Influenza Vaccines Assessment and project team , Next-generation influenza vaccine impact modelling contributors

Research Article | published 30 Jun 2025 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1004655>

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 26 July 2025)

#### **[Cholera crisis persists: A call for integrated health strategies](#)**

Musawer Khan, Kamil Ahmad Kamil

Viewpoints | published 23 Jul 2025 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0013272>

### **PLoS One**

<http://www.plosone.org/>

[Accessed 26 July 2025]

#### **[Attitudes, beliefs, and practices regarding complementary and alternative medicine use: Influenza vaccine intake](#)**

Dala N. Daraghmeh, Ahmad Salah, Nasim Hamdan, Abdallah Zamareh

Research Article | published 23 Jul 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0320412>

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 26 July 2025]

[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States**

July 22, 2025 vol. 122 no. 29

<https://www.pnas.org/toc/pnas/122/28>

*Brief Report* July 17, 2025

#### **[Infectious disease outbreaks drive political mistrust](#)**

Ore Koren and Nils B. Weidmann

*Abstract*

The COVID-19 pandemic has renewed attention to the far-reaching social implications of emerging infectious diseases, an issue with historical parallels in the transformative effects of the Black Plague and Spanish Flu. However, the potential for epidemics to reshape political trust and fuel instability has remained underexplored. This study leverages a novel dataset on zoonotic disease outbreaks—

including Ebola, Marburg, H1N1, and the Black Plague—and geolocated Afrobarometer survey data from dozens of African states to investigate whether exposure to these deadly outbreaks alters public confidence in political institutions. Estimating the average-treatment-effect-in-the-treated with coarsened exact matching, we find that individuals with an infectious disease outbreak experience significant declines in trust toward the political establishment, especially the president, parliament, and ruling party (reductions of 0.2, 0.18, and 0.22 points, respectively, on a four-point scale). These findings, consistent across various spatial and temporal windows, provide robust empirical evidence that deadly infectious disease outbreaks can exacerbate political polarization and undermine political stability. The study emphasizes the critical need for policy strategies that integrate public health preparedness with efforts to preserve and rebuild institutional trust during outbreaks.

### **PNAS Nexus**

Volume 4, Issue 5, May 2025

<https://academic.oup.com/pnasnexus/issue/4/5>

### **PNAS - Proceedings of the National Academy of Sciences of the United States**

July 22, 2025 vol. 122 no. 29

<https://www.pnas.org/toc/pnas/122/28>

*Applied Physical Sciences*

#### **Resilience of science after austerity**

Ye Sun and others

PNAS Nexus, Volume 4, Issue 6, June 2025, pgaf122, <https://doi.org/10.1093/pnasnexus/pgaf122>

In 2009, many governments implemented austerity measures. This often resulted in restrictions on science funding, increasing competition for funds. Here, we study the allocation of funding across universities by using a competitiveness measure from complexity science based on the bipartite network of universities and scientific subjects. Drawing on a comprehensive data set of 43,430 UK-funded grants between 2006 and 2020, a period covering the onset and relaxation of austerity, we provide two main results. First, we find that the effect of austerity on university grant income depended on research competitiveness: highly competitive universities increased grant income under austerity, while low-ranked universities lost income. Then, we study the resilience of science to austerity exploiting the natural experiment arising from the 2015 UK general election, when austerity was relaxed unexpectedly. We discover that the resilience of researchers at less competitive universities was surprisingly high. The number and size of grant applications grew more after 2015 at less competitive universities, increasing their grant income. Overall, results show that our network-based measure is a better proxy for research competitiveness than aggregate grant income across scientific subjects.

### **Prehospital & Disaster Medicine**

Volume 40 - Issue 3 - June 2025

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

### **Preventive Medicine**

Volume 197 August 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/197/suppl/C>

[Reviewed earlier]

**Proceedings of the Royal Society B**

July 2025 Volume 292 Issue 2051

<https://royalsocietypublishing.org/toc/rspb/current>

*Table of Contents*

[New issue; No digest content identified]

**Public Health**

Volume 244 July 2025

<https://www.sciencedirect.com/journal/public-health/vol/244/suppl/C>

[Reviewed earlier]

**Public Health Ethics**

Volume 18, Issue 2, July 2025

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Genomics**

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

**Public Health Reports**

Volume 140 Issue 2-3, March-April/May-June 2025

<https://journals.sagepub.com/toc/phrg/140/2-3>

[Reviewed earlier]

**Qualitative Health Research**

Volume 35 Issue 9, August 2025

<https://journals.sagepub.com/toc/QHR/current>

[New issue; No digest content identified]

**Research Ethics**

Volume 21 Issue 3, July 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

**Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 26 July 2025]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

21 Jul 2025

**[Ethics in public health surveillance: progress and challenges in the Americas](#)**

Opinion and analysis | Spanish |

21 Jul 2025

**[Paths to mainstreaming gender and intersectionality in neglected tropical disease programs](#)**

Opinion and analysis | Spanish |

**[Social protection strategies for people with tuberculosis in Latin America: \(re\) thinking policies and practices](#)**

Opinion and analysis | Portuguese

### **Risk Analysis**

Volume 45, Issue 5 Pages: 969-1185 May 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 26 July 2025]

[No new digest content identified]

### **Royal Society Open Science**

July 2025 Volume 12 Issue 7

<https://royalsocietypublishing.org/toc/rsos/current>

[Reviewed earlier]

### **Science**

Volume 389| Issue 6758| 24 Jul 2025

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

### **Science and Engineering Ethics**

Volume 31, Issue 4 August 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-4>

[Reviewed earlier]

### **Science Translational Medicine**

Volume 17| Issue 808| 23 Jul 2025

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

## **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 26 July 2025]

[No new digest content identified]

## **Social Science & Medicine**

Volume 380 September 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/380/suppl/C>

[Reviewed earlier]

## **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 26 July 2025]

[No new digest content identified]

## **Theoretical Medicine and Bioethics**

Volume 46, Issue 3 June 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-3>

[Reviewed earlier]

## **Travel Medicine and Infectious Diseases**

Volume 66 July–August 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/66/suppl/C>

[Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 30, Issue 7 Pages: i-iv, 577-748 July 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

## **Vaccine**

Volume 60 11 July 2025

<https://www.sciencedirect.com/journal/vaccine/vol/60/suppl/C>

[Reviewed earlier]

## **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 26 July 2025]

*Open Access Review*

**[Literature Review and Policy Recommendations for Single-Dose HPV Vaccination Schedule in China: Opportunities and Challenges](#)**

by Kexin Cao and Yiu-Wing Kam

Vaccines 2025, 13(8), 786; <https://doi.org/10.3390/vaccines13080786> - 24 Jul 2025

*Abstract*

Cervical cancer remains a significant global public health challenge, with human papillomavirus (HPV) as its primary cause. In response, the World Health Organization (WHO) launched a global strategy to eliminate cervical cancer by 2030 and, in its 2022 position paper, recommended a single-dose [...]

*Open Access Review*

### **[A Narrative Review of College Meningococcal Vaccination Mandates Across the United States](#)**

by Jessica Presa, Eva Jodar, Monica Ochapa, Tim A. Mullenix, Sharon E. Barrett and Alejandro Cane  
Vaccines 2025, 13(8), 784; <https://doi.org/10.3390/vaccines13080784> - 24 Jul 2025

*Abstract*

In the United States, adolescents and young adults between the ages of 16 and 23 have high rates of serogroup B meningococcal infections due to an elevated risk for those attending college. This review examines meningococcal vaccination requirements and recommendations for college students [...]

*Open Access Article*

### **[Survey on Awareness and Attitudes Toward Maternal Immunization Against Influenza, Pertussis, Respiratory Syncytial Virus, and Group B Streptococcus Among Pregnant Women in Japan](#)**

by Kazuya Hiiragi, Soichiro Obata, Masafumi Yamamoto, Mai Shimura, Chika Akamatsu, Azusa Tochio, Mayumi Hagiwara, Aya Mochimaru, Ai Kiyose, Miki Tanoshima, Etsuko Miyagi and Shigeru Aoki  
Vaccines 2025, 13(8), 779; <https://doi.org/10.3390/vaccines13080779> - 23 Jul 2025

*Abstract*

Background/Objective: Maternal immunization is highly recommended, particularly in developed countries. However, its awareness among pregnant women in Japan remains low. This study aimed to assess the awareness and attitudes toward maternal immunization among pregnant women in Japan and to identify the factors [...]

*Open Access Review*

### **[100-Day Mission for Future Pandemic Vaccines, Viewed Through the Lens of Low- and Middle-Income Countries \(LMICs\)](#)**

by Yodira Guadalupe Hernandez-Ruiz, Erika Zoe Lopatynsky-Reyes, Rolando Ulloa-Gutierrez, María L. Avila-Agüero, Alfonso J. Rodriguez-Morales, Jessabelle E. Basa, Frederic W. Nikiema and Enrique Chacon-Cruz

Vaccines 2025, 13(7), 773; <https://doi.org/10.3390/vaccines13070773> - 21 Jul 2025

*Abstract*

The 100-Day Mission, coordinated by the Coalition for Epidemic Preparedness Innovations (CEPI) and endorsed by significant international stakeholders, aims to shorten the timeframe for developing and implementing vaccines to 100 days after the report of a new pathogen. This ambitious goal is outlined [...]

*Open Access Article*

### **[Vaccination in Aged Care in Australia: A Retrospective Study of Influenza, Herpes Zoster, and Pneumococcal Vaccination](#)**

by Stephen Wiblin, Yuen Lai, Natalie Soulsby and Jodie Hillen

Vaccines 2025, 13(7), 766; <https://doi.org/10.3390/vaccines13070766> - 20 Jul 2025

*Abstract*

Background: Older adults living in aged care are at risk of poor health outcomes due to influenza, pneumococcal disease, and herpes zoster infections. Despite these conditions being vaccine-preventable, little is known about vaccine uptake rates in the residential elderly care setting in [...]

July 2025 Volume 28 Issue 7 p979-1140  
<https://www.valueinhealthjournal.com/current>  
[Reviewed earlier]

## **World Development**

Volume 192 August 2025

<https://www.sciencedirect.com/journal/world-development/vol/192/suppl/C>

*Research article Open access*

### **[A machine learning approach to assessing multidimensional poverty and targeting assistance among forcibly displaced populations](#)**

Angela C. Lyons, Alejandro Montoya Castano, Josephine Kass-Hanna, Yifang Zhang, Aiman Soliman  
Article 107013

.....  
.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

## ***Pre-Print Servers***

### **arxiv**

<https://arxiv.org/>

[Accessed 26 July 2025]

*[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]*

[No new digest content identified]

### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 26 July 2025]

[No new digest content identified]

### **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 26 July 2025]

### **[Cost-Effectiveness of Infant and Maternal RSV Immunization Strategies](#)**

Javad Moradpour Taleshi, Marina Vineta Paramo, Allison Watts, Mark Chilvers, Jeffrey ManHay Wong, Jolanta Piszczek, Lea Separovic, Jia Hu, Danuta Skowronski, Pascal M. Lavoie, Hind Sbihi  
medRxiv 2025.06.27.25330432; doi: <https://doi.org/10.1101/2025.06.27.25330432> Revision

**Tuberculosis infection screening recommendations for targeted immunotherapies: comparison of U.S. prescribing information, clinical resources and quality measures**

Matthew T. Murrill, Gustavo E. Velásquez, John D. Szumowski, Allison Phillips, Annie Kim, Jinoos Yazdany, Eric T. Roberts, Anand R. Habib, Haiyan Ramirez Batlle, Jorge Salazar, Daniel J. Minter, Janice K. Louie, Joel D. Ernst  
medRxiv 2025.07.25.25332013; doi: <https://doi.org/10.1101/2025.07.25.25332013>

**Multicountry genomic analysis underscores regional cholera spread in Africa**

Gerald Mboowa, Nathaniel Lucero Matteson, Collins Kipngetich Tanui, Mpanga Kasonde, Guyguy Kusanzangana Kamwiziku, Olusola Anuoluwapo Akanbi, Jucunú Johane Elias Chitio, Mathews Kagoli, René Ghislain Essomba, Alisen Ayitewala, Isaac Ssewanyana, Valentina Josiane Ngo Bitoungui, Adrienne Aziza Amuri, Andrew S Azman, Olajumoke Atinuke Babatunde, Blaise Mboringong Akenji, Anaïs Broban, Espoir Bwenge Malembaka, Francis Ongole, Chimaobi Emmanuel Chukwu, Nália Ismael, Otridah Kapon, Osvaldo Laurindo, Placide Kingebeni Mbala, Georges Alain Etoundi Mballa, Imelda Carlos Zulfa Miambo, Alex Ansaye Mwanyongo, Grace Najjuka, Joseph Mutale, Kunda Musonda, Allan Muruta Niyonzima, Mirriam Ethel Nyenje, Michael Popoola, Doreen Mainza Shempela, Christiane Medi Sike, Sofião Manjor Siteo, Dorcas Waruguru Wanjohi, Placide Okitayemba Welo, Mtisunge Yelewa, Sebastian Yennan, Lucius Ziba, CholGEN Consortium, Joseph Ephram Bitilinyu-Bangoh, Roma Chilengi, Hamsatou Hadja, Jide Idris, José Paulo Maurício Langa, Daniel Mukadi-Bamuleka, Susan Nabadda, Amanda K Debes, David A Sack, Yenew Kebede Tebeje, Shirlee Wohl, Sofonias Kifle Tessema  
medRxiv 2024.11.15.24317392; doi: <https://doi.org/10.1101/2024.11.15.24317392> Revision

**A scoping review of definitions and conceptualizations of ecosyndemics in syndemic research**

Yassir Gnaoui, M. Nienke Slagboom, Jessica C. Kieft-de Jong, Mariëlle A. Beenackers  
medRxiv 2025.07.24.25331762; doi: <https://doi.org/10.1101/2025.07.24.25331762>

**Wastewater concentrations of rotavirus RNA are associated with infection and vaccination metrics in the USA**

Elana M. G. Chan, Alessandro Zulli, Alexandria B. Boehm  
medRxiv 2025.07.21.25331943; doi: <https://doi.org/10.1101/2025.07.21.25331943>

**Science and knowledge translation strategies during public health emergencies: A systematic review of RCTs**

Melody Taba, Michael Anthony Fajardo, Eliza Ferguson, Rachael Keast, Jocelyne M Basseal, Kirsten McCaffery, Carissa Bonner  
medRxiv 2025.07.21.25331954; doi: <https://doi.org/10.1101/2025.07.21.25331954>

**Measles RNA detection in wastewater solids**

Abigail P. Paulos, Alessandro Zulli, Bridgette Shelden, Dorothea Duong, Alexandria B. Boehm, Marlene K. Wolfe  
medRxiv 2025.07.18.25331801; doi: <https://doi.org/10.1101/2025.07.18.25331801>

**Agricultural Work, Malaria Prevalence, and Mediating Factors: A Cross-Sectional Analysis of Data from 15 Sub-Saharan African Countries to Inform Risk Stratification and Intervention Planning**

Ifeoma D. Ozodiegwu, Grace Legris, Chilochibi Chiziba, Laurette Mhlanga  
medRxiv 2025.07.21.25331926; doi: <https://doi.org/10.1101/2025.07.21.25331926>

**OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]  
[No new digest content identified]

### **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 26 July 2025]

*Study Protocol Open Access*

**[Guidance on the economic evaluation of the health impacts of climate action: a literature review protocol.](#)**

[version 1; peer review: awaiting peer review]

Patricia Cubi-Molla, et al.

*Abstract*

This paper outlines the protocol for a systematic literature review on the economic evaluation of health impacts from climate action. As climate policies increasingly integrate health co-benefits, methodological inconsistencies between environmental and health economics create challenges for policy evaluation. This review aims to identify, synthesize, and appraise existing methods used to assess the health impacts of climate mitigation and adaptation policies. The study will explore valuation approaches, methodological robustness, and best practices to inform globally consistent guidelines. By providing a structured framework for analysis, this protocol supports the development of evidence-based economic evaluation methods that bridge climate and health policy domains.

\*

\*

\*

\*

### **Think Tanks**

**Brookings** [to 26 July 2025]

<http://www.brookings.edu/>

*Reports, Events*

*No new digest content identified.*

**Center for Global Development** [to 26 July 2025]

<https://www.cgdev.org/>

*All Research*

*No new digest content identified.*

**Chatham House** [to 26 July 2025]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [to 26 July 2025]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 26 July 2025]

[https://www.csis.org/  
Reports \[Selected\]](https://www.csis.org/Reports/[Selected])  
*No new digest content identified.*

**Kaiser Family Foundation** [to 26 July 2025]  
[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)  
*Newsroom*

**[Poll: New Tax and Budget Law Remains Largely Unpopular; Nearly Half Say It Will Hurt Their Families, though Republicans and MAGA Supporters Are More Optimistic](#)**

July 24, 2025 News Release

Nearly half (46%) of the public says that they expect the new tax and budget law signed by President Trump earlier this month to generally hurt them and their families, nearly twice the share (26%) who say it will generally help, a new KFF Health Tracking Poll finds.

**[Victoria DeFrancesco Soto Joins KFF Board of Trustees](#)**

July 21, 2025 News Release

San Francisco – KFF announced today that Dr. Victoria DeFrancesco Soto has joined KFF’s Board of Trustees. DeFrancesco Soto is the Dean of the Clinton School of Public Service at the University of Arkansas and previously served as Assistant Dean at the LBJ School of Public Affairs at the University...

**McKinsey Global Institute** [to 26 July 2025]  
<https://www.mckinsey.com/mgi/overview>

**[McKinsey Technology Trends Outlook 2025](#)**

July 22, 2025 -

Which frontier technologies matter most for companies in 2025? Our annual tech trends report highlights the latest technology breakthroughs, talent trends, use cases, and their potential impact on companies across sectors.

**ODI [Overseas Development Institute]** [to 26 July 2025]  
<https://odi.org/en/publications/>  
*Publications [Selected]*  
*No new digest content identified.*

**Pew Research Center** [to 26 July 2025]  
<https://www.pewresearch.org/>  
*Latest Publications [Selected]*  
*No new digest content identified.*

**Rand** [to 26 July 2025]  
<https://www.rand.org/pubs.html>  
*Published Research [Selected]*  
*No new digest content identified.*

**Urban Institute** [to 26 July 2025]  
<https://www.urban.org/publications>  
**[New Research Publications - Selected](#)**

**World Economic Forum** [to 26 July 2025]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....  
.....

## **Public Consultations/Call for Inputs/Call for Papers**

### **Draft guideline on the quality aspects of mRNA vaccines**

**EMA** Draft: consultation open **Consultation dates: 31/03/2025 to 30/09/2025**

Reference Number: EMA/CHMP/BWP/82416/2025

#### *Summary:*

This guideline addresses the quality aspects of mRNA vaccines. It addresses specific aspects regarding the manufacturing process, characterisation, specifications and analytical control of mRNA vaccines, as well as the definition of starting materials, active substance and finished product for mRNA vaccines. Additional regulatory considerations are provided for changes in existing mRNA vaccine strains, bivalent and multivalent vaccines, self-amplifying mRNA vaccines, other delivery systems and use of platform technology/prior knowledge. The scope of this guideline is applicable to mRNA vaccines against infectious diseases. Other mRNA-based medicinal products are out of scope of this guideline, although relevant parts of this guideline may be applicable to those. It is not intended to address specific requirements for mRNA vaccines to be used in clinical trials, however the scientific principles described may also be applicable during pharmaceutical development.

### **Agency Information Collection Activities; Proposed Collection; Comment Request; Emergency Use Authorization of Medical Products**

A Notice by the Food and Drug Administration on 07/14/2025 **Comment period ends 09/12/2025.**

OMB Control Number 0910-0595—Extension

#### **SUPPLEMENTARY INFORMATION:**

This information collection helps support implementation of Agency policies applicable to the authorization for medical products for use in emergencies under sections 564, 564A, and 564B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360bbb-3, 360bbb-3a, and 360bbb-3b). For more information regarding emergency use authorization (EUA), visit our website at <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization>.

The FD&C Act permits the Commissioner of Food and Drugs (the Commissioner) to authorize the use of unapproved medical products for humans and animals, or unapproved uses of approved medical products for humans and animals, during an emergency declared under section 564 of the FD&C Act. The data to support issuance of an EUA must demonstrate that, based on the totality of the scientific evidence available to the Commissioner, including data from adequate and well-controlled clinical trials (if available), it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing a serious or life-threatening disease or condition (21 U.S.C. 360bbb-3(c)).

Also, under section 564 of the FD&C Act, the Commissioner may establish conditions on issuing an authorization that may be necessary or appropriate to protect the public health...

### **ICH - E21 Inclusion of Pregnant and Breastfeeding Women in Clinical Trials; International Council for Harmonisation; Draft Guidance for Industry; Availability**

A Notice by the Food and Drug Administration on 07/21/2025 **Comment period ends 09/19/2025**

### *SUMMARY:*

...The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "E21 Inclusion of Pregnant and Breastfeeding Women in Clinical Trials." The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance is intended to provide general principles on the conduct of clinical trials that include pregnant and breastfeeding women to inform evidence-based decisions on safe and effective use of medicinal products by these populations.

The draft guidance includes approaches to generating data that support informed decision-making on the safety, dosing, and efficacy of medicinal products during pregnancy and breastfeeding. Additionally, the draft guidance includes recommendations for recruiting and retaining pregnant and breastfeeding women in clinical trials, while reducing burden and harm on these participants.

### *Background*

...The recommendations found in this draft guidance are the product of the Efficacy Working Group of the ICH. Comments about this draft will be considered by FDA and the Efficacy Expert Working Group.

The draft guidance outlines strategies and considerations for developing and implementing clinical studies that include pregnant or breastfeeding women. This draft guidance includes approaches to plan, collect data, evaluate outcomes, and monitor safety of pregnant and breastfeeding women participating in clinical trials safely and ethically. Additionally, the draft guidance includes recommendations for recruiting and retaining pregnant and breastfeeding women in clinical trials. The draft guidance also emphasizes reduction of burden on pregnant and breastfeeding women participating in these trials.

This draft guidance has been left in the original ICH format. The final guidance will be reformatted and edited to conform with FDA's good guidance practices regulation (21 CFR 10.115) and style before publication.

## **Solicitation of Nominations for Appointment to the Advisory Council for the Elimination of Tuberculosis**

A Notice by the Centers for Disease Control and Prevention on 07/11/2025. **Nominations must be received no later than September 30, 2025**

### *SUMMARY:*

In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), is seeking nominations for membership on the Advisory Council for the Elimination of Tuberculosis (ACET). ACET consists of 10 experts including the Chair in fields associated with public health, epidemiology, immunology, infectious disease, pulmonary disease, pediatrics, tuberculosis, microbiology, and preventive health care delivery.

### *SUPPLEMENTARY INFORMATION:*

The Advisory Council for the Elimination of Tuberculosis (ACET) provides advice and recommendations regarding the elimination of tuberculosis (TB) to the Secretary, Department of Health and Human Services (HHS); the Assistant Secretary for Health, HHS; and the Director, Centers for Disease Control and Prevention (CDC). ACET (a) makes recommendations on policies, strategies, objectives, and priorities; (b) addresses development and application of new technologies; (c) provides guidance and review of CDC's TB prevention research portfolio and program priorities; and (d) reviews the extent to which progress has been made toward eliminating TB.

\*

\*

\*

\*

***Contents [click to move among sections]***

***:: Milestones, Perspectives***

:: WHO  
:: Organization Announcements  
:: Journal Watch  
:: Pre-Print Servers

\* \* \* \*  
\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*  
\* \* \* \*